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RIASSUNTO 
Gli approcci per lo sviluppo di vaccini hanno avuto notevoli progressi durante l‘ultimo 
secolo. Tutti i vaccini commerciali in questo momento disponibili sono stati realizzati 
seguendo l‘approccio tradizionale e si basano, quindi, sull‘utilizzo di patogeni morti o 
attenuati, di subunità purificate dai patogeni come tossine detossificate mediante 
trattamenti chimici o genetici, di antigeni purificati o di polisaccaridi coniugati a 
proteine. L‘approccio tradizionale, tuttavia, non ha avuto successo per la produzione 
di vaccini contro i patogeni che non possono essere coltivati in vitro e per i quali non 
esistono ovvi antigeni protettivi immunodominanti. Nell‘ultimo decennio la genomica 
ha rivoluzionato il mondo della ricerca dei vaccini grazie allo sviluppo di nuove 
tecnologie per il sequenziamento del DNA. 
L‘approccio genomico per la produzione di vaccini elabora le informazioni 
ottenute dal sequenziamento dell‘intero genoma del patogeno d‘interesse. Le 
migliaia di geni presenti in tutta la sequenza del DNA sono identificate in seguito ad 
analisi computerizzata che consente di predire con buona accuratezza sia la 
localizzazione cellulare di nuovi open reading frame (ORFs) che la funzione delle 
risultanti proteine e le loro omologie con fattori di virulenza noti prodotti da altri 
patogeni (analisi in silico). I risultati di questo tipo di analisi includono non solo tutti gli 
antigeni in precedenza identificati mediante approcci convenzionali ma anche la 
scoperta di nuovi antigeni. Proteine secrete o espresse sulla superficie esterna del 
patogeno, cioè facilmente ―riconoscibili‖ dal sistema immunitario, saranno 
selezionate quali candidati per lo sviluppo di un vaccino. La loro capacità di 
provocare una risposta immunologica efficace sarà valutata in un lungo percorso di 
saggi in vivo o in vitro prima di poter attraversare tutto l‘iter che porta all‘utilizzo 
nell‘uomo. L‘approccio genomico per sviluppare vaccini partendo dall‘informazione 
genetica del patogeno è definito ―Reverse Vaccinology‖. La Reverse Vaccinology è 
stata utilizzata per lo sviluppo di vaccini contro numerosi batteri patogeni come gli 
Streptococchi di gruppo A e di gruppo B, Neisseria meningitidis, Escherichia coli 
extraintestinale e Streptococcus pneumoniae.  
Gli studi strutturali rientrano in una nuova fase della vaccinologia che è definita 
Structural Vaccinology. La Structural Vaccinology consiste nella caratterizzazione 
strutturale dei fattori di virulenza di patogeni ad alta priorità mediante cristallografia ai 
raggi X o spettroscopia di risonanza magnetica nucleare (NMR) e nella mappatura 
degli epitopi sulle strutture risolte. La comprensione degli aspetti strutturali alla base 
dell‘interazione anticorpo/epitopo stabilisce, in secondo momento, la base per il 
design razionale dei vaccini, in modo da ottimizzare la produzione industriale su 
larga scala, l‘omogeneità conformazionale e la stabilità dei nuovi antigeni. 
Il progetto di dottorato rientra nell‘ambito della Structural Vaccinology. Il lavoro 
di dottorato è stato focalizzato su un antigene del patogeno Neisseria meningitidis ed 
un antigene del patogeno Streptococcus pneumoniae, entrambi identificati mediante 
la ―Reverse Vaccinology‖. 
Neisseria meningitidis rappresenta la principale causa dell‘insorgere e della 
diffusione della meningite tra i bambini e gli adolescenti. Neisseria meningitidis è un 
batterio diplocco Gram-negativo dotato di capsula polisaccaridica che colonizza il 
tratto superiore della via naso-faringea negli uomini. Il principale fattore di virulenza è 
la capsula polisaccaridica. Il vaccino meningococcico in uso è un vaccino 
tetravalente coniugato contro i sierogruppi A, C, Y e W135; tuttavia il vaccino non è 
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efficace contro il sierogruppo B. Una delle strategie usate per la realizzazione di un 
vaccino contro il sierogruppo B prevede la realizzazione di vaccini basati su antigeni, 
una soluzione che è efficace per la protezione contro l‘infezione dal ceppo omologo 
all‘antigene utilizzato, ma che risulta incapace di proteggere contro l‘infezione da 
batteri eterologhi a causa dell‘elevata variabilità antigenica dei patogeni. L‘approccio 
genomico ha consentito di superare tutti i problemi legati ai metodi tradizionali, infatti 
la Reverse Vaccinology applicata a Neisseria meningitidis ha portato allo sviluppo di 
un vaccino pentavalente costituito da cinque nuovi antigeni: factor H binding protein 
(fHbp), NadA, GNA2132, GNA1030 e GNA2091. Durante il primo e il terzo anno di 
dottorato il lavoro è stato focalizzato su fHbp.  
fHbp è una lipoproteina esposta in superficie di circa 28 kDa costituita da 255 
residui amminoacidici; oltre ad essere uno dei componenti del vaccino pentavalente 
contro il sierogruppo B di Neisseria meningitidis, è essenziale per la patogenesi 
perché consente al batterio di sopravvivere e crescere nel sangue umano attraverso 
il legame con il fattore H, un regolatore negativo del pathway alternativo del 
complemento. Il rivestimento della superficie batterica con il fattore H consente al 
patogeno di mimare i tessuti umani e di sfuggire alla lisi mediata dall‘attivazione del 
complemento. fHbp può essere classificata in tre varianti caratterizzate da diversa 
sequenza amminoacidica. Questa diversità ha un forte impatto sulle proprietà 
immunologiche della proteina, poiché ogni variante induce una forte immunità solo 
contro i ceppi di meningococco che presentano alleli omologhi. 
Inizialmente studi immunologici sono stati eseguiti con la variante 1 di fHbp; 
sieri policlonali ed un anticorpo monoclonale (Mab502) sono stati utilizzati per 
identificare gli epitopi lineari e conformazionali e sulla base dei risultati ottenuti la 
proteina è stata suddivisa in tre regioni: la regione A (1-101), la regione B (101-164) 
e la regione C (164-255). Gli epitopi battericidi sono localizzati prevalentemente nel 
dominio BC della proteina e i residui chiave per il riconoscimento antigene-anticorpo 
sono il residuo Arg204 e la regione 146-149. 
Per comprendere la conformazione degli epitopi protettivi, studi strutturali in 
soluzione mediante spettroscopia di risonanza magnetica nucleare (NMR) sono stati 
compiuti sulla variante 1 di fHbp. La proteina è costituita da due -barrel indipendenti 
tenuti insieme da un corto linker; saggi immunologici hanno mostrato che gli epitopi 
battericidi sono localizzati sul dominio C-terminale della proteina. La disponibilità 
della struttura in soluzione ha consentito di effettuare la mappatura degli epitopi 
anche mediante esperimenti NMR confermando i dati precedentemente ottenuti 
medianti saggi immunologici.  
Durante il lavoro di dottorato è stata studiata l‘interazione tra fHbp e il fattore H 
mediante esperimenti NMR bidimensionali. Recentemente è stata risolta la struttura 
cristallografica del complesso fHbp-fH (domini 6-7). I dati rivelano che i residui chiave 
di fHbp coinvolti nell‘interazione sono i residui E218 e E239 e che il complesso è 
tenuto insieme da numerose interazioni di tipo elettrostatico tra fHbp e il dominio 6 
del fattore H. Gli esperimenti NMR in soluzione consentono di studiare l‘interazione 
in un contesto molto più simile a quello in vivo; inoltre, gli esperimenti sono stati 
condotti usando due costrutti diversi del fattore H, il costrutto formato dai domini 67 
(CCP67) ed il costrutto formato dai domini 567 (CCP567). In un primo momento si è 
studiata l‘interazione tra fHbp ed il costrutto CCP567 attraverso esperimenti NMR 
bidimensionali analizzando le perturbazioni dei chemical shift sugli spettri 1H–15N 
TROSY-HSQC della proteina marcata con l‘isotopo radioattivo 15N in seguito 
all‘aggiunta di quantità crescenti del fattore H. 
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La maggior parte dei residui perturbati nella struttura cristallografica che 
costituiscono l‘area di contatto tra le due proteine risultano perturbati anche dai dati 
NMR, due eccezioni importanti sono rappresentate dai residui E219 e E239 che 
vengono perturbati solo marginalmente dalla presenza del fattore H. La concordanza 
dei dati NMR e X-ray rivela che anche in soluzione è mantenuta l‘interazione tra la 
proteina ed i domini 6 e 7 del fH. Tuttavia il numero totale dei residui esposti in 
superficie perturbati nelle misure NMR definisce un‘ampia area di contatto rispetto a 
quella definita nella struttura cristallografica. Un primo gruppo di residui è localizzato 
nel linker che connette i due domini della proteina e molti residui localizzati 
all‘interfaccia tra i due domini. La sensibilità di tali residui alla presenza del fattore H 
suggerisce che durante la formazione del complesso fHbp-CCP567 potrebbero 
avvenire riarrangiamenti molecolari della proteina. Una seconda regione è formata 
da residui la cui localizzazione sulla superficie proteica è compatibile con eventuali 
contatti con il dominio 5 del fH. Per confermare quest‘ipotesi gli stessi esperimenti 
sono stati eseguiti utilizzando il costrutto CCP67 del fH. L‘analisi rivela che il numero 
di residui perturbati rimane invariato, escludendo la possibilità che il dominio 5 possa 
stabilire contatti specifici con la proteina e suggerendo che l‘interazione con il fH è 
limitata ai domini 67. I dati NMR ottenuti sono in accordo con gli studi precedenti di 
mappatura degli epitopi eseguiti su fHbp. Beernink e colleghi hanno dimostrato che 
Gly121 e Lys122, due residui esposti in superficie e localizzati nel loop che 
congiunge gli strand 7 e 8 del dominio N-terminale della proteina, sono riconosciuti 
da anticorpi monoclonali come Jar3 e Jar5, che inibiscono il legame al fH. In 
accordo, questi residui risultano perturbati nella titolazione mediante spettroscopia 
NMR con i costrutti del fH. Inoltre, è stato dimostrato attraverso esperimenti FACS 
che l‘interazione con il fH non è influenzata dall‘interazione della proteina con 
l‘anticorpo MAb502 (11). I residui coinvolti nell‘interazione con tale anticorpo risultano 
infatti non perturbati durante gli esperimenti NMR, confermando che non esiste 
sovrapposizione tra i siti di legame del fH e dell‘anticorpo. I dati NMR possono 
essere utilizzati come punto di partenza per uno studio di mutagenesi sito-diretta dei 
residui perturbati allo scopo di identificare altri residui chiave coinvolti nell‘interazione 
tra il fH e fHbp. 
Durante il terzo anno del dottorato l‘attività di ricerca è stata focalizzata sullo 
studio del possibile ruolo di fHbp nei processi di assorbimenti del ferro dall‘ambiente 
durante la patogenesi del microorganismo. L‘analisi strutturale della proteina 
evidenzia una forte similitudine con le lipocaline, proteine trovate in piante, funghi, 
batteri, vertebrati e invertebrati che sono coinvolte in numerosi processi biologici 
incluso il legame a molecole coinvolte nei processi di reclutamento del ferro 
dall‘ambiente chiamate siderofori. I siderofori sono piccole molecole sintetizzate dai 
batteri e dai funghi in condizioni di stress in presenza di poco ferro; essi fungono da 
agenti chelanti specifici per tale metallo. Il ruolo dei siderofori durante la patogenesi è 
di rendere disponibile il ferro alla cellula batterica catturando il metallo dall‘ambiente, 
per questo motivo queste piccole molecole rappresentano un possibile bersaglio per 
il sistema immunitario della cellula ospite. Molti batteri hanno evoluto la capacità di 
utilizzare siderofori prodotti da altri microorganismi, ad esempio Neisseria 
meningitidis, pur non producendo siderofori esprime una proteina di superficie, FetA, 
nota essere un recettore per l‘enterobactina, un sideroforo prodotto dai batteri 
enterici. Sulla base di queste osservazioni è stato studiato il possibile ruolo di fHbp 
come siderophore binding protein mediante spettroscopia NMR, in particolare è stata 
studiata la possibile interazione con tre siderofori: enterobactina, yersiniabactina e la 
salmochelina. Lo studio, come nel caso della mappatura del sito di binding con il 
7 
 
fattore H, è stato eseguito analizzando le perturbazioni sullo spettro 1H–15N- HSQC 
della proteina marcata con l‘isotopo radioattivo 15N in seguito all‘aggiunta di quantità 
crescente di sideroforo. Sono state eseguite diverse titolazioni in modo da 
investigare la possibile interazione con diversi siderofori, per gli esperimenti NMR 
sono stati usati enterobactina, Fe-enterobactina, Fe-Yersiniabactina e Fe-
Salmochelina. I dati NMR rivelano un‘affinità solo per la Fe-enterobactina, l‘aggiunta 
di tale sideroforo alla proteina risulta in un progressivo incremento della larghezza di 
riga dei segnali di alcuni residui sugli spettri, che scompaiono al rapporto molare 
proteina:sideroforo pari a 1:1.5. Tutti i residui perturbati sono localizzati sul dominio 
C-terminale della proteina. I dati NMR sono stati, in seguito, usati per generare un 
modello del complesso fHbp-enterobactina usando il programma HADDOCK2.0. I 
dati ottenuti, inoltre, rivelano che la regione che interagisce con l‘enterobactina non è 
sovrapposta alla regione contenente il sito di legame per il fH, questo suggerisce un 
possibile ruolo di fHbp nei processi di acquisizione del ferro del meningococco e 
nella sopravvivenza del microorganismo nella cellula ospite durante la patogenesi.  
Durante il secondo anno di dottorato il lavoro è stato focalizzato su un 
antigene del patogeno Streptococcus pneumoniae, RrgB. 
Streptococcus pneumoniae è un batterio diplococco Gram-postitivo e rappresenta la 
principale causa dell‘insorgere delle malattie del tratto respiratorio fra cui la polmonite 
ed è causa minoritaria dell‘insorgere di malattie invasive fra cui la meningite. Il 
principale fattore di virulenza per questo microrganismo è rappresentato dalla 
capsula polisaccaridica, la cui differente composizione chimica determina la divisione 
in vari sierogruppi. Il vaccino disponibile in commercio è un vaccino polivalente 
coniugato ma non universale. Recentemente, sulla superficie batterica di 
Streptococcus pneumoniae sono stati identificati pili, i risultati ottenuti dagli studi 
effettuati evidenziano un ruolo chiave per queste strutture superficiali nei processi di 
adesione del patogeno. La produzione del pilo di Streptococcus pneumoniae è 
regolata dall‘operone rlrA costituito da sette geni: un gene codificante un regolatore 
trascrizionale positivo; i geni srtB, srtC e srtD, codificanti enzimi richiesti per 
l‘assemblaggio del pilo sulla parete cellulare; e i geni rrgA, rrgB e rrgC, codificanti le 
tre proteine strutturali del pilo. L‘analisi strutturale del pilo mediante microscopia crio-
elettronica mostra che i pili sono organizzati in strutture coiled-coil costituite da 
almeno due protofilamenti, in cui RrgB costituisce il componente principale e forma lo 
scheletro del pilo, mentre RrgA e RrgC sono ancorate allo scheletro proteico del pilo 
e coinvolte nei fenomeni di adesione alle cellule ospiti. Studi immunologici hanno 
rivelato che le tre subunità del pilo conferiscono protezione e quindi sono considerati 
come potenziali candidati per vaccini di nuova generazione basati su proteine. Da un 
punto di vista biochimico le proteine dei pili dei batteri Gram-positivi sono 
caratterizzate dalla presenza di legami isopeptidici intramolecolari e intermolecolari. I 
legami intramolecolari si formano tra le catene laterali di un residuo di Asn e di un 
residuo di Lys, mentre i legami intermolecolari sono fondamentali per la 
polimerizzazione del pilo e si formano tra le catene laterali di un residuo di Thr 
presente nel motivo LPXTG all‘estremità C-terminale di una subunità RrgB e di un 
residuo di Lys localizzato all‘estremità N-terminale della subunità successiva. 
RrgB è una proteina di superficie batterica di 665 amminoacidi composta di 
diversi domini: il peptide leader (1-30), il dominio D1 (30-184), il dominio D2 (185-
327), il dominio D3 (328-446), il dominio D4 (447-627) e il dominio LPxTG, 
contenente il motivo riconosciuto dalle sortasi (628-665). Recentemente è stata 
risolta la struttura cristallografica dei domini D2, D3, D4 (187-627); tutti i domini 
presentano un folding IgG-like e sono caratterizzati dalla presenza di un legame 
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isopeptidico intramolecolare. Saggi immunologici hanno inoltre consentito di 
identificare il dominio D1 come la regione che conferisce maggiore protezione, 
tuttavia non esistono dati strutturali sul dominio D1 e quindi non è possibile 
approfondire gli aspetti strutturali alla base del riconoscimento antigene-anticorpo. 
Durante il lavoro di dottorato si è lavorato sulla caratterizzazione strutturale del 
dominio D1 di RrgB mediante esperimenti NMR in collaborazione con il CERM di 
Firenze allo scopo di comprendere gli aspetti molecolari alla base della maggiore 
immunogenicità di questo dominio. Sono stati effettuati esperimenti NMR 
bidimensionali e tridimensionali su campioni marcati con gli isotopi radioattivi 15N e 
13C/15N utilizzando spettrometri 500, 600, 700, 800 e 900 MHz, gli spettri sono stati 
analizzati mediante il software Cara. I dati ottenuti dall‘analisi e dall‘interpretazione 
degli spettri sono stati utilizzati per la determinazione della struttura tridimensionale 
della proteina attraverso l‘uso del programma CYANA2.1. La struttura è stata 
raffinata mediante il programma AMBER10.0 utilizzato per la minimizzazione 
energetica. Il dominio D1 presenta un folding  sandwich IgG-like. Il core proteico è 
caratterizzato da sette  strand paralleli e antiparalleli raggruppati in due  sheet 
disposti l‘uno contro l‘altro e circondati da due lunghi segmenti; un -elica è 
localizzata all‘interno del primo segmento e due  strand sono localizzati all‘interno 
del secondo segmento. Una delle caratteristiche che differenzia il dominio D1 dai 
domini D2, D3 e D4 è l‘assenza di legami isopeptidici intramolecolari e la presenza di 
molte regioni flessibili. La flessibilità del D1 potrebbe essere fondamentale nei 
processi di riconoscimento specifico antigene-anticorpo. Infatti, la plasticità strutturale 
della proteina potrebbe essere correlata all‘abilità del dominio D1 di andare incontro 
a cambi conformazionali locali, di adattare la struttura in modo da ottimizzare 
l‘interazione con gli anticorpi e d‘incrementare l‘affinità e la specificità dei processi di 
riconoscimento antigene-anticorpo. 
Una ricerca per le proteine strutturali omologhe, effettuata usando il server 
DALI, ha portato all‘identificazione di tre proteine con folding simile: il dominio C-
terminale CNA3 di BcpA che rappresenta la pilina principale di Bacillus cereus, il 
dominio N-terminale della pilina SpaA di Corynebacterium diphtheriae e il dominio N1 
della pilina minore di Streptococcus agalactiae GBS52. Tutte queste proteine non 
presentano legami isopeptidici intramolecolari, tuttavia solo nel caso della SpaA il 
dominio che corrisponde al D1 è localizzato all‘estremità N-terminale così come il D1 
nella proteina intera RrgB. La sovrapposizione delle due strutture rivela, inoltre, la 
stessa orientazione spaziale delle catene laterali dei residui di Lys localizzati nel pilin 
motif YPKN e coinvolte nella formazione del legame isopeptidico intermolecolare 
durante la polimerizzazione del pilo; entrambe le lisine non sono completamente 
esposte, in particolare nel dominio D1 la catena laterale della lisina è proiettata in 
una cavità formata tra il core della proteina ed un loop flessibile. Questo dato 
suggerisce che anche durante la polimerizzazione del pilo siano necessari dei cambi 
conformazionali del dominio D1. Il ruolo del residuo di lisina, così identificato, nel 
processo di polimerizzazione del pilo è stato confermato mediante esperimenti di 
mutagenesi sito-diretta. 
In conclusione, questo studio fornisce informazioni addizionali riguardanti le 
caratteristiche delle proteine dei pili e pone le basi per il design razionale di nuovi 
antigeni per implementare il vaccino proteico contro le malattie da pneumococco. Le 
nuove informazioni strutturali e dinamiche acquisite su RrgB suggeriscono che la 
flessibilità conformazionale del dominio D1 sia fondamentale per i processi di 
riconoscimento antigene-anticorpo. 
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Tutte le informazioni ottenute durante questi anni hanno permesso di elucidare 
alcuni aspetti riguardanti le funzioni biologiche di alcuni antigeni. Tutti i dati ottenuti 
potranno essere utilizzati in futuro per il design razionale di nuovi antigeni allo scopo 
di creare proteine con maggiore immunogenicità e stabilità in modo da ottimizzare la 
produzione industriale su larga scala. Questo lavoro di ricerca fornisce, quindi, un 
contributo nell‘ambito della Structural Vaccinology, che sfrutta le tecniche di biologia 
strutturale per incrementare, tramite ingegneria biomolecolare, l‘efficacia e la stabilità 
dei vaccini attualmente disponibili sul mercato o in fase di sviluppo clinico. 
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Introduction 
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1.1. Historical background 
Despite advances in the treatment of infectious diseases, pathogenic 
microorganisms are still the most important threat to health worldwide. Remarkable 
progresses have been made in vaccine development in the last 200 years and 
vaccination has prevented illness and death for millions of individuals. However, 
efficacious treatments against many infectious disease agents or reemerging 
infections still need to be discovered. For these reasons, novel vaccines together 
with new ways to discover and approach them are needed. The oldest vaccines 
currently available are based on killed or live-attenuated microorganisms and on 
toxins detoxified by chemical treatments. The knowledge of the pathogenesis of 
many microorganisms, the identification of the main virulence factors, and the 
characterization of the immune response after infection have been fundamental for 
the design of new vaccines based on highly purified antigenic components, on 
genetically detoxified toxins, and on polysaccharides or oligosaccharides conjugated 
to proteins (1). 
The first important innovation in the vaccine field was the introduction of 
molecular biology and genetic techniques which allowed the development of two 
efficacious recombinant vaccines: the hepatitis B vaccine, which is based on a highly 
purified capsid protein (2), and the vaccine against Bordetella pertussis, based on 
three highly purified proteins, including a genetically detoxified toxin (3, 4). A second 
revolution in vaccine design started with the genomic era. The ―shotgun sequencing‖ 
strategy was initially developed and applied to several genome projects allowing in 
1995 the completion of the first sequence for a free-living organism (Haemophilus 
influenzae) by The Institute for Genomic Research (TIGR) (5). Nowadays, new 
sequencing technologies are emerging (6). Thanks to these technical advances, in 
the last few years the number of available genomes has grown considerably with 725 
bacterial sequences completed, and more than 2000 other microorganisms being 
sequenced in various laboratories around the world (GOLD Genomes OnLine 
database at http://www.genomesonline.org/). This panel of bacterial genomes 
already covers most of the pathogens impacting heavily on human health. By the 
vaccinology point of view, the complete genome of a bacterium represents a large 
reservoir of genes encoding for potential antigens that can be selected, screened and 
tested as vaccine candidates. Therefore, potentially surface-exposed proteins can be 
identified in a reverse manner, starting from the genome rather than from the 
microorganism. This novel approach has been termed ―reverse vaccinology‖ (7) (Fig. 
1). In addition, the availability of complete annotated genome sequences, coupled 
with bioinformatics, has spawned the new scientific discipline of ―comparative 
genomics‖ that can be applied to different strains, species and genera and 
represents a powerful approach for studying differences in phenotype, host range, 
and molecular evolution of virulence. 
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Figure 1. Reverse vaccinology approaches. The reverse vaccinology approach consists in mining a genome sequence of a 
single bacterial isolates. The pan-genome reverse vaccinology approach represents an advance, since it highlights the potential 
of looking at more than one genome for the same bacterial species (i.e. sequencing more than one isolates) to overcome the 
problems represented by gene presence and variability. The comparative reverse vaccinology approach consists in comparing 
pathogenic (pink bacteria) and non-pathogenic (yellow bacteria) genome sequences in order to select those antigens that are 
specific for pathogens and that might be involved in pathogenesis. Once potential vaccine candidates are identified in silico, the 
selected ORFs are amplified, cloned in expression vectors, purified and used to immunize mice. The immune sera are used in 
in vitro assays to measure the ability of specific antibodies to kill the pathogen (e.g. the bactericidal assay, which was used for 
MenB); the immunized animals can be also used for challenging experiments with a lethal dose of the pathogen to measure the 
protection rate. The best candidates selected by this screening process will enter the final vaccine development step. 
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1.2. The application of Reverse Vaccinology: Neisseria meningitidis 
The concept of reverse vaccinology was applied for the first time to serogroup 
B Neisseria meningitidis (MenB). N. meningitidis is the major cause of meningitis and 
sepsis, two devastating diseases that can kill children and young adults within hours, 
despite the availability of effective antibiotics. It is a Gram-negative bacterium that 
colonizes asymptomatically the upper nasopharinx tract of about 5–15% of human 
population. However, in a significant number of cases, the bacterium can traverse the 
epithelium and reach the bloodstream causing septicemia. From the blood 
meningococcus is able to cross the blood brain barrier and infect the meninges, 
causing meningitis (8)(Fig. 2). 
 
Figure 2. Colonization of nasopharinx by N. meningitidis and entry into the bloodstream and cerebrospinal fluid. 
 
N. meningitidis can be classified in 13 serogroups on the basis of the chemical 
composition of the capsule polysaccharide. However, more than 95% of total cases 
of invasive disease are caused by five major serogroups: A, B, C, Y and W135. 
Vaccines against serogroups A, C, Y and W135 were developed in the 1960s by 
using the purified capsular polysaccharide as antigen. Second generation, 
conjugated vaccines are now being introduced. The chemical composition of the 
polysaccharide of serogroup B, which resembles a molecule present in human 
tissues, makes a polysaccharide-based vaccine poorly immunogenic and a possible 
cause of auto-immunity. In the last 40 years a lot of efforts have been directed to the 
identification of meningococcus B antigens as basis of new vaccines. However, the 
high variability of these proteins among the different MenB strains represents a 
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serious obstacle to the production of a globally effective anti-MenB vaccine (9). As a 
consequence there are no effective vaccines available for the prevention of MenB 
disease, which is responsible of one third of meningococcal disease in the United 
States of America, and up to 80% of cases in Europe. To identify novel vaccine 
candidates against MenB, it was applied the reverse vaccinology approach based on 
the whole-genome sequencing of a serogroup B strain (10)(Fig. 3). 
Briefly, the sequence of the 
virulent MC58 strain was determined by 
the shotgun strategy (11). Based on the 
concept that surface-exposed antigens 
are susceptible to antibody recognition 
and are therefore the most suitable 
vaccine candidates, the complete MenB 
genome was screened using 
bioinformatic algorithms in order to 
select open reading frames (ORFs) 
coding for putative surface-exposed or 
secreted proteins. Genome mining 
allowed the prediction of approximately 
600 potential antigens, 350 of which 
were successfully expressed in 
Escherichia coli, purified and used to 
immunize mice. The antisera obtained 
were tested by FACS and ELISA to 
evaluate the surface localization of the 
antigens. In addition, the antisera were 
tested for bactericidal antibodies (BCA), 
a property known to correlate with 
protection in humans. Ninety-one novel 
surface-exposed antigens were 
identified, 28 of which induced 
bactericidal antibodies. Several of the 
antigens previously identified using 
conventional approaches showed strain 
variability or were only expressed in 
some strains, and most of them were 
effective only against the homologous 
strains. Therefore, the potential vaccine 
candidates identified were evaluated for 
degree of sequence variability among 
multiple isolates and serogroups of N. 
meningitidis. The vaccine antigens 
selected by reverse vaccinology were 
prioritized based on their ability to 
induce broad strain coverage as inferred by bactericidal activity or observed in 
passive protection in the infant rat model. 
Five antigens selected by this approach were combined into one multi-
component vaccine, to increase the breadth of the vaccine coverage and avoid 
selection of escape mutants. Moreover, to facilitate large-scale production and to 
further increase their immunogenicity, four of the five antigens were expressed as 
Figure 3. Flow chart of MenB vaccine development. 
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fusion proteins, GNA2132 with GNA1030, GNA2091 with GNA1870. Neisseria 
Adhesin A (NadA) was included as single antigen. 
In order to properly test whether the MenB vaccine formulation is able to 
induce protection against diverse MenB strains, a very large collection of clinical 
isolates representing the MenB global population diversity has been assembled and 
characterized and 85 strains selected for the bactericidal assay. The vaccine 
formulated with alum hydroxide induces bactericidal antibodies in mice against 78% 
of the 85 genetically diverse strains; coverage can be increased to 90% using 
different adjuvants (12). The MenB vaccine combined with OMV from the New 
Zealand strain have been tested in human clinical trials with very promising results, 
suggesting that a vaccine able to prevent meningococcus B can become a reality. 
While the vaccine is in clinical development, research efforts are focused on the 
functional and immunological characterization of the main vaccine antigens.  
Neisseria Adhesin A belongs to the Oca family (Oligomeric coiled-coil 
adhesins) a group of autotransporters adhesins characterized by the presence of a 
coiled-coil motif that possibly mediates the oligomerization process. Consistently to 
the predicted structural features, NadA forms high-molecular weight oligomers, stable 
in denaturing conditions. The role of NadA in mediating the binding to human 
epithelial cells was initially reported by using the recombinant purified protein (13). 
Further characterization revealed that E. coli strains expressing the oligomeric form 
of NadA are able to interact with Chang conjunctiva epithelial cells. The use of a 
meningococcus nadA isogenic knockout mutant confirmed the role of this protein in 
the intimate association of the bacteria with host cells. Interestingly, the NadA gene is 
not ubiquitous in Neisseria strains, being present only in 50% of the strains analyzed, 
but it is always present in strains of hyper-virulent clonal complexes ET5, ET37 and 
A4, whereas it is absent from Lineage III, in N. gonorrhoeae, N. cinerea and N. 
lactamica. The gene clusters in three well conserved alleles, whose overall identity 
ranges from 96% to 99%; bactericidal activity is not influenced by allele diversity (13). 
NadA is recognized by children convalescent sera suggesting that it is expressed in 
vivo and immunogenic (14). These evidences support the hypothesis that NadA is an 
important virulence factor in the pathogenesis of Neisseria highlighting the additional 
role that NadA antibodies could have in preventing meningococcus colonization. 
GNA1870 (also named fHBP, factor H Binding Protein or LP2086) is a 26.9 
kDa lipoprotein exposed on the surface of meningococcus. The protein is expressed 
at different levels in the different strains that have been therefore classified as high, 
intermediate and low expressors. Sequencing of the gene in several strains, 
representative of the genetic and geographic diversity of the N. meningitidis 
population, showed that the protein is present as three variants. Conservation within 
each variant ranges between 91.6% and 100%, while conservation among the three 
variants can be as low as 62.8%. Bactericidal activity is variant-specific and 
antibodies against a recombinant form of the protein elicit complement-mediated 
killing of strains that carry the same variant, whereas the activity against strains 
carrying a different variant is very low or absent (15). Immunological characterization 
indicated that bactericidal antibodies were directed against conformational epitopes 
mainly located in the C-terminal domain of the protein, including the residues 100–
255 (16). Nuclear Magnetic Resonance (NMR) spectroscopy was applied to solve its 
solution structure. The protein is composed of two independent barrels connected by 
a short linker (17). Sequence alignment of the three representative variants together 
with the analysis of the GNA1870 structure shows that, as opposed to integral outer 
membrane proteins, regions of extensive variability of the protein are not associated 
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with mobile loops but instead are spread on the whole molecule, suggesting that the 
entire protein is exposed to immune recognition. GNA1870 is able to bind the human 
complement factor H (fH) and for this reason has been renamed fHbp. Binding to fH 
allows the bacterium to escape the alternative pathway of complement activation and 
survive and grow in human blood. Level of fH binding correlates with the expression 
level of fHbp and when factor H is bound complement activation is reduced, enabling 
bacterial survival. Antibodies to GNA1870 can induce bacterial killing through a dual 
mechanism: directly, by activation of the classical complement pathway and indirectly 
by diverting fH away from the bacterial surface (18). 
GNA2132 protein is predicted to be a novel surface-exposed lipoprotein. 
Serum antibody from mice immunized with recombinant GNA2132 are able to bind 
on the surface of diverse N. meningitidis strains and elicited complement-mediated 
bactericidal activity (10, 15). Moreover, anti-GNA2132 antibody elicited deposition of 
human C3b on the bacterial surface and passively protected infant rats against 
meningococcal bacteremia (19). GNA2132 is thus a promising vaccine candidate for 
prevention of meningococcal disease. 
 
1.3. A pilus-based vaccine against Streptococcus pneumoniae 
The reverse vaccinology approach was also applied to Streptococcus 
pneumoniae to identify vaccines candidates. S. pneumoniae is one of the most 
important human pathogens, accounting for considerable morbidity and mortality 
rates worldwide. Pneumococcus is the most common etiologic agent of community-
acquired pneumonia, as well as bacterial meningitis, otitis media, and sepsis. It is a 
Gram-positive bacterium that colonizes the nasopharynx of children and healthy 
adults. S. pneumoniae produces a range of different colonization and virulence 
factors including the polysaccharide capsule, surface proteins and enzymes, and the 
pneumolysin toxin, that allow the bacterium to escape the host immune system and 
cause disease (Fig. 4). 
The polysaccharide capsule is probably 
the most important pneumococcal 
virulence factor, as it protects the bacteria 
from phagocytosis; it is crucial for 
colonization, prevents mechanical 
removal by mucus and can also restrict 
autolysis and reduce exposure to 
antibiotics. Capsule polysaccharides are 
highly heterogeneous and, thus far, at 
least 93 different capsular serotypes have 
been described, according to their unique 
serological profiles and chemical 
structures. Conjugated polysaccharide-
based vaccines are available and 
extremely effective against serotypes 
included in the formulation (20). However, 
the vaccine was primarily developed for 
US and Europe, whereas in developing 
countries where non-vaccine types cause 
most of the disease, the coverage is low. 
Furthermore, few years after the introduction of Prevenar glycoconjugated vaccine, 
Figure 4. Streptococcus pneumoniae virulence is 
multi-faceted. 
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emergence of non-vaccine serotypes has been reported, thus posing some concern 
on the long-term effectiveness of these types of vaccines (21). To broaden the 
protection, the development of a protein-based pneumococcal vaccine could be a 
feasible and preferable alternative. However, so far the identification of protein 
antigens suitable for the formulation of a universal pneumococcal vaccine has 
remained elusive. In order to fill this gap ―reverse vaccinology‖ were used to identify 
all possible surface-exposed and immunogenic molecules encoded by S. 
pneumoniae. The whole genome sequence was scanned and 130 potential ORFs 
with significant homology to surface proteins and virulence factors of other bacteria 
were selected (22). From this set, 108 ORFs were expressed and purified for mice 
immunization and evaluated as vaccine candidates. A subset of six novel antigens 
was able to induce protective antibodies against pneumococcal challenge in a mouse 
sepsis model. Furthermore, the six predictive targets showed a high degree of cross-
reactivity against the majority of capsular antigens that are expressed in vivo and are 
immunogenic during human infection. 
Interestingly, this methodology resulted in the identification of a genomic locus 
in the pathogenic strain TIGR4 that possesses all the typical features of a pilus-
encoding island. This locus, named rlrA pathogenicity islet (or pilus 1, PI-1) contains 
seven genes: rlrA, encoding a RofA-like transcriptional regulator, rrgA, rrgB and rrgC, 
which encode the LPxTG cell-wall anchored pilin subunits, and srtC-1, srtC-2 and 
srtC-3 coding for the three sortases involved in the linkage and assembly of the pilus 
structure on the bacterial surface.  
 
                                  
 
 
Figure 5: Pilus 1. A) Immunogold localization of RrgB in pilus-1 of S. pneumoniae TIGR4 using α-RrgB antibobies. B) 
Schematic representation of pilus-1 subunits arrangement. C) Schematic representation of PI-1 islet. 
α RrgB 
C 
B 
18 
 
It has been demonstrated that the major pilin subunit, forming the backbone of the 
pilus, is RrgB, while RrgA and RrgC are the two ancillary pilins, probably localized at 
the opposite extremes of the pilus; RrgA is the pilus adhesin, while the role of RrgC is 
still under investigation (23, 24) (Fig. 5).  
The deletion of all three pilus-associated sortase genes, srtC-1, srtC-2 and 
srtC-3, completely prevent pilus biogenesis, and expression of SrtC-1 alone is 
sufficient to covalently associate RrgB subunits to one another as well as linking the 
RrgA adhesion and RrgC to the polymer (25). In particular, Falker‘s studies 
suggested that, SrtC-1 and SrtC-2 act as redundant pilus subunit polymerases, with 
SrtC-1 processing all three pilus subunits proteins, while SrtC-2 only RrgA and RrgB. 
In contrast, SrtC-3 seems to have no pilus polymerase activity, but appears to be 
required for wild type focal presentation of the pili on the bacterial surface. 
Antibodies raised against the three Rrg subunits were tested in immuno-
electron microscopy experiments allowing for the first time the visualization of 
filamentous structures on the surface of the pneumococcus (23). Pneumococcal pili 
appear as long, thin filaments, protruding from the surface of the bacterium in a hair-
like fashion (Fig. 5A). These peculiar features of being abundant and extraordinarily 
well exposed onto the cell wall and capsular polysaccharide of the bacterium – much 
more than any other surface-exposed molecule –make pilus subunits exceptional 
candidates for vaccine development. As expected, both active and passive 
immunization studies confirmed that the three pilus subunits are able to confer highly 
significant protection against lethal challenge with S. pneumoniae TIGR4 strain (26). 
From a functional viewpoint, pneumococcal PI-1 pili were shown to be involved in 
mucosal colonization and virulence in animal models, as well as to play a role in the 
host inflammatory response (23). However, a major limitation of pilus subunits as 
vaccine candidates is represented by the fact that the rlrA islet is not widespread in 
pneumococcal isolates. In order to identify additional pilus types in pneumococcus 
that could be used to complement pilus 1 subunits for the development of a universal 
pilus-based vaccine, the reverse vaccinology approach was extended to the whole 
collection of publicly available S. pneumoniae genomes. This global genomic 
approach eventually led to the identification of a second pilus island (pilus islet 2, PI-
2) in a serotype 1 strain (27). Interestingly, as revealed by genome analyses, some 
strains contain both pilus islet 1 and pilus islet 2, and in these strains both pili are 
surface exposed and independently assembled. Recent data provide evidence that in 
vitro the pilus encoded by PI-2 of S. pneumoniae is involved in adherence to lung 
alveolar cells, while in vivo the PI-2 subunits elicit protection against challenge with 
PI-2 positive strains (Ruggiero et al., personal communication). Since pneumococcal 
PI-1 covers between 33% and 50% (in the antibiotic resistant subset) of the strains, 
and PI-2 is contained in approximately 16% of the strains, the combination of the two 
pili antigens could cover about 49–66% of currently circulating pneumococcal 
isolates. 
Although additional widely conserved vaccine candidates still need to be 
identified to offer a universal protection against pneumococcal infections, the role of 
pili in pneumococcal pathogenesis, in addition to strain coverage, represents an 
eligible criterion for these antigens to be considered as valuable components of the 
next generation of protein-based vaccines. 
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1.4. The need for “Structural Vaccinology” 
The use of native antigens has proven remarkably successful against a wide 
range of pathogens, but not against all agents for which vaccines are needed. The 
pathogens for which we have successful vaccines share certain characteristics. In 
general they are agents against which humoral immunity is protective and their 
surface antigens do not vary more quickly than new variants can be incorporated into 
updated vaccines. Examples include diphtheria, poliovirus and hepatitis B virus, 
which have not undergone significant antigenic change over many decades. Despite 
great progress, we still face some very tough pathogens that so far have eluded 
vaccine design efforts. These pathogens usually have the common property of 
showing to the immune system antigens of high variability, which allows escape from 
immune recognition. A typical example is HIV, which changes its antigenic surface 
daily, making it impossible to design a conventional vaccine. These pathogens 
usually have two types of surface epitopes: those that are highly visible by the 
immune system, conventionally named immunodominant epitopes (which have the 
property of being highly variable), and those that do not mutate and are common to 
all strains. The latter are usually completely invisible or poorly visible to the immune 
system, and the immunity against them cannot be elicited by conventional 
vaccinology (28). Moreover, for some complex pathogens, in the impoverished 
settings where new vaccines are urgently needed, the cost of production and 
distribution of vaccines is a major barrier to use. Even in the developed world, where 
expense is less of an issue, the number of immunizations a child receives is 
becoming increasingly burdensome. Optimizing vaccine antigens by combining the 
tools of genetic engineering with the insights provided by high resolution structural 
analysis may allow us to overcome these barriers. 
Structural biology is increasingly being applied to vaccine development 
focusing on determining and understanding the structural basis of immunodominant 
and immunosilent antigens, to enable the rational design of peptide mimetics of 
bactericidal epitopes (29, 30). This new vaccinology field is named ―Structural 
Vaccinology‖. The explosion of genome and proteome data, as well as improved 
protein expression, purification, and structural determination technologies, has led to 
the rapid development of the field of structural vaccinology (31)(Fig. 6). 
Approximately 30,000 high-resolution protein structures are available in public 
databases (predominantly for soluble proteins), and several initiatives have been 
established to pursue high-throughput characterization of protein structures on a 
genome-wide scale (32). The structure-based design of antiviral therapeutics is a 
well-established approach that has led to the development of drugs directed toward 
the active sites of the HIV-1 protease (33) and influenza neuraminidase (34). 
One important goal of structural vaccinology is to selectively present the 
conserved determinants of complex and variable antigens. Distinguishing structural 
components that elicit protective and disease enhancing immunity could avoid 
vaccine-mediated exacerbation of disease. Using high resolution structures, antigens 
can be designed to be more efficiently produced and stably stored than native 
molecules, thereby lowering costs and eliminating barriers to distribution. By 
engineering antigens amenable for use in combination vaccines, immunization 
regimens can be simplified. By knowing which parts of an antigen must be retained to 
preserve basic characteristics and which can be altered, vaccine antigens can be 
modified more rapidly in response to changing epidemiology. 
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Figura 6. Flow chart of structural vaccinology approach 
The biophysical, biochemical, and genetic engineering technologies needed 
for structural vaccinology are sophisticated, but the concept is simple: first, study the 
native molecular architecture of neutralization determinants of antigens by NMR 
spectroscopy and X-ray crystallography; and then, use this knowledge to modify the 
molecules and engineer immunogens that are optimally designed for inclusion in 
protective vaccines. Success of structural vaccinology will require the application of 
high throughput methods to generate a large number of antigenic structures and 
assays to predict their effectiveness as immunogens. With current knowledge, it is 
already possible to optimize protein antigens for efficient production, conformational 
homogeneity, and stable storage. However, fully realizing the potential of structure 
based design of vaccine antigens will require longer-term basic research into the 
structural determinants of immunodominance and immunogenicity. This research 
must take into account the diversity of the antibody repertoire generated not only in a 
single individual, but also in those of different genetic backgrounds and histories of 
antigen exposure (30). Moreover, matching the rational design of antigens to 
advances in the rational design of adjuvants can enable a new generation of 
vaccines that are more safe, broadly protective, practical, and affordable than those 
available today. 
An example of structural vaccinology approach was the resolution structure of 
the fHbp, one of the MenB antigens identified by reverse vaccinology to elicit 
protective human immune responses. The structure of fHbp has enabled the 
identification of epitopes recognized by bactericidal fHbp-specific antibodies raised 
against fHBP variants, and these epitopes have been used as the basis for 
engineering a chimeric fHbp vaccine candidate (30, 35). 
 
1.5. Aim of research 
In the ―Structural Vaccinology‖ contest the objective of the PhD project was 
the functional and structural characterization of surface proteins from pathogenic 
bacteria for the improvement of vaccines against these agents. During the PhD the 
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work was focused on two antigens from different pathogens: factor H binding protein 
(fHbp) from N. Meningitidis and RrgB from S. Pneumoniae. 
In the first case I focused my research on the study of the interaction between 
fHbp and factor H by using NMR spectroscopy in order to identify key residues 
engaged in the interaction. Moreover, I pointed the attention also on a new potential 
biological function of this antigen; in particular, I investigated about a possible role of 
the protein in the iron recruitments from the environments during the pathogenesis. 
Based on the work already published by Scarselli M. about the rational design of 
chimeric fHbp, all the data collected could be used in order to engineer new vaccine 
candidate. 
My research focused, on another antigen from S.pneumoniae, RrgB. The work 
proceeded with the solution structural characterization by NMR spectroscopy of the 
RrgB D1 domain. The solution structure of the D1 domain could improve the 
knowledge about the distribution of protective epitopes on the protein surface in order 
to understand the molecular basis for the immunogenity of the protein. In addition, 
the new acquired structural information on the RrgB molecule pave the way to future 
rational design attempts to generate new RrgB-based molecules to implement a 
protein-based vaccine against pneumococcal disease. 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
Methodologies Aspects 
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2.1 NMR and high-resolution structure determination 
X-ray crystallography and NMR spectroscopy are the two main techniques 
that can provide structures of macromolecules at atomic resolution. Both techniques 
are well established and play already a key role in structural biology as a basis for a 
detailed understanding of molecular functions. Whereas X-ray crystallography 
requires single crystals, NMR measurements are carried out in solution under 
conditions that can be as close as possible to the physiological state. Furthermore, 
the analysis through NMR spectroscopy easily allows the characterization under 
several, different experimental conditions, such as different ionic strength and pH. 
NMR measurements not only provide structural data but also can supply information 
on the internal mobility of proteins on various time scales, on protein folding and on 
intra-, as well as, intermolecular interactions. 
The principles of NMR structure determination can be summarized as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
The power of NMR technique respect the other spectroscopic techniques, results 
from the fact that each NMR active nucleus gives rise to an individual signal in the 
spectrum that can be resolved by multi-dimensional NMR techniques. This becomes 
more difficult for larger molecular structures (more than 50,000 Da) and puts a 
practical limit to the molecular size that can be studied in detail by NMR. 
 
2.2. Preparation of the protein solution sample 
The first step to solve the three dimensional structure of biological 
macromolecules is the preparation of the protein solution, since a highly purified 
protein preparation is required. An inhomogeneous preparation and/or aggregation of 
the protein as well as low molecular weight protonated impurities may severely hard 
the structure determination. The first step in every protein NMR study therefore 
involves optimization of the measurement conditions as pH, ionic strength, and 
temperature that can often be adjusted to mimic physiological conditions. The 
macromolecule under study should be stable in the chosen conditions for many 
Preparation of protein solution 
sample 
NMR Spectroscopy 
Sequence Resonance Assignment 
 
Collection of conformational 
constraints 
Calculation of the 3D structure 
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weeks. Proteins with a molecular weight larger than 10 kDa must be isotope enriched 
in 15N and 13C for an efficient structure determination. 15N and 13C are used because 
the most abundant carbon isotope (12C) does not give a NMR signal and the most 
abundant nitrogen isotope (14N) has undesired NMR properties. 
 
2.3. NMR spectroscopy  
NMR spectra of biological macromolecules contain hundreds or even 
thousands of resonance lines which cannot be resolved in a conventional one-
dimensional spectrum (1D). Further, the interpretation of NMR data requires 
correlations between different nuclei, which are implicitly contained in 1D spectrum 
but often difficult to extract. Multidimensional NMR spectra provide both, increased 
resolution and correlations which are easy to analyse. 
The crucial step in increasing the dimensionality of NMR experiments lies in 
the extension from one to two dimensions. A higher dimensional NMR experiment 
consists of a combination of two-dimensional (2D) experiments. All 2D NMR 
experiments use the same basic scheme which consists of the four following, 
consecutive time periods: 
excitation - evolution - mixing - detection 
During the excitation period the spins are prepared in the desired state from which 
the chemical shifts of the individual nuclei are observed during the evolution period 
t1. In the mixing period the spins are correlated with each other and the information 
on the chemical shift of one nucleus ends up on another nucleus of which the 
frequency is measured during the detection period t2. A resonance in the 2D 
spectrum, such as a cross peak, represents a pair of nuclei that suitably interact 
during the mixing time. 
The extension from a 2D to a n-dimensional (nD) NMR experiment consists in 
the combination of (n-1) two-dimensional experiments which contains only one 
excitation and one detection period but repeats the evolution and mixing times (n-1) 
times. A typical nD NMR experiment thus follows the scheme: 
 
excitation - (evolution - mixing)n–1 - detection 
where the bracket repeats (n–1) times. Only during the detection period the signal is 
physically measured and this period is often referred to as the direct dimension in 
contrast to the evolution periods which are referred to as indirect dimensions. 
The NMR multidimensional measurements almost always use protons (1H) 
and depending on the isotope labelling, 13C and/or 15N nuclei. A 3D spectrum can, for 
example, be obtained by correlating the amide groups with the -carbon nuclei 
attached to 15N. The chemical shifts of these carbon nuclei are used to spread the 
resonances from the 2D plane into a third dimension. The sensitivity obtainable with 
these types of nuclei greatly varies even if the sample is fully isotope labelled with 
13C or 15N. The proton offers the best sensitivity and for this reason constitutes the 
preferred nucleus for detection of the NMR signal. The other nuclei are usually 
measured during evolution periods of multidimensional NMR experiments and their 
information is transferred to protons for detection. For small proteins (less than 
10kDa), it is not required to label the sample with 13C or 15N. In this case the 
assignment strategy makes use of a combination of 2D homonuclear 1H NMR 
experiments such as COSY/TOCSY, and NOESY/ROESY spectra. COSY- and 
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TOCSY-type experiments, where COSY stands for COrrelation SpectroscopY and 
TOCSY for Total Correlation Spectroscopy, correlate different nuclei via J coupling 
(36, 37) In proteins which are isotope labelled with 15N and 13C J couplings between 
1H, 15N and 13C allow through-bond correlations across the peptide bond. 
Through-space correlations are instead measured via the nuclear Overhauser 
effect (NOE) and provide the basis for geometric information required to determine 
the structure of a macromolecule (38). The NMR method for proteins structure 
determination relies on a dense network of distance constraints derived from NOEs 
between nearby hydrogen atoms in the protein (39). NOEs connect pairs of hydrogen 
atoms separated by less than about 5 Å. In contrast to COSY-type experiments the 
nuclei involved in the NOE correlation can belong to amino acid residues that may be 
far apart along the protein sequence but close in space. For molecules with a 
molecular weight of more than 5 kDa the intensity of an NOE is approximately 
proportional to r-6 and to the molecular weight, where r is the distance between the 
two interacting spins. NMR experiments which measure the NOE are often referred 
to as NOESY experiments where NOESY stands for NOE SpectroscopY (40). 
 
2.4. Sequence Resonance Assignment 
For a detailed analysis of the information content of NMR spectra nearly 
complete assignments of signals in the spectra to individual atoms in the molecule 
are a requirement. The application of multidimensional NMR spectroscopy allowed 
the development of general strategies for the assignment of signals in proteins. All 
procedures use the known protein sequence to connect nuclei of amino acid residues 
which are neighbours in the sequence. As mentioned before, for unlabelled proteins 
smaller than 10 kDa the combination of the [1H,1H]-COSY or TOCSY, used for the 
sequential assignment, with the [1H, 1H]-NOESY spectrum allows the assignment of 
most proton NMR signals to individual protons (39). 
For larger proteins extensive signal overlap prevents complete assignments of 
all 1H signals in proton spectra. This barrier can be overcome with 3D NMR 
technique and uniformly 13C and 15N labelled proteins. The resonance assignment of 
single (15N or 13C) labelled proteins using 3D experiments is basically an extension of 
Wüthrich‘s strategy which exclusively relies on homonuclear 1H NMR experiments. 
With these methods, systems with molecular weights up to approximately 30 kDa can 
be studied. In 13C, 15N-labeled proteins a sequential assignment strategy is based on 
through-bond correlations across the peptide-bond between sequential amino acids. 
This procedure circumvents the use of NOESY spectra already in the assignment 
step. Most of these correlation experiments use the three types of nuclei 1H, 15N, 13C 
and are referred to as triple resonance experiments. 
The 3D triple resonance experiments exclusively correlate the resonances of 
the peptide backbone (HN(i), N(i), C(i), H(i), C(i-1), CO(i) and CO(i-1)). Figure 1 
shows the spin system of the peptide backbone and indicates the size of the coupling 
constants used for magnetization transfer in double 13C-, 15N-labelled proteins. The 
3D experiments used to identify the backbone resonances are, usually, HNCA or 
HNCACB, HN(CO)CA or HN(CO)CACB, HNCO, HN(CA)CO and HNHA (41). The 
HNCACB for example, correlates each H-15N group with both the intra- and the 
neighbouring inter-residue C and and Cβ. These four types of connectivity are 
discriminated using the HN(CO)CACB experiment, in which only the inter-residue 
HN-C and Cβ couplings are observed. 
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Similar strategy can be used to assign the other resonances in the other triple 
resonance spectra.  
 
Figure 1. Spin system of the peptide backbone and the size of the 
1
J and 
2
J coupling constants that are used for 
magnetization transfer in 
13
C-, 
15
N-labelled proteins. 
In the case of proteins with a molecular weight larger than 30 kDa the use of 
TROSY-type experiments (42) is necessarily. TROSY experiment can reduce the 
signal loss, which is the direct consequence of the slower correlation tumbling of 
large molecules which results in faster relaxation and consequently broader lines in 
the NMR spectrum. TROSY uses constructive interference between different 
relaxation mechanisms and works best at the highest available magnetic field 
strengths in the range of 700 to 900 MHz proton resonance frequency. With TROSY 
the molecular size of proteins accessible for detailed NMR investigations has been 
extended several folds. The TROSY technique benefits a variety of triple resonance 
NMR experiments as the 3D HNCA and HNCOCA (43) and the TROSY-based 
NOESY experiments for the collection of structural constraints are also available 
(44). CRINEPT-TROSY is another recently developed technique for even larger 
proteins. It can yield a further significant gain in sensitivity for molecular sizes above 
200kDa. The best magnetic field strengths for CRINEPT-TROSY are in the range 
900-1000MHz proton resonance frequencies. Since the H and C/ chemical shifts 
have been assigned, 3D H(C)CH-TOCSY and (H)CCH-TOCSY (45) experiments are 
then used to link the side chain spin systems to the backbone assignments. These 
two experiments provide information for the assignment of the side chain protons and 
of the side chain carbons, respectively. 
A complete set of backbone chemical shifts for all H, C, C and CO 
resonances can be used to predict the secondary structure of the protein (46). One 
technique in particular, the Chemical Shift Index (CSI) (47), has been widely used for 
the quantitative identification and location of secondary structure in proteins. The 
method relies on the fact that the chemical shifts of the different nuclei in the protein 
backbone are related both to the type of amino acid and to the nature of the 
secondary structure they are located in. By comparing the actual chemical shift for a 
nucleus in a specific amino acid with a reference value, it is possible to predict in 
what secondary structure element the nucleus resides. The reference value that you 
compare with is the random coil chemical shift for that same nucleus in the same 
amino acid. Another system for the secondary structure prediction is TALOS+ 
(Torsion Angle Likelihood Obtained from Shift and sequence similarity) which allowed 
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to predict phi and psi backbone torsion angles using a combination of five kinds (HA, 
CA, CB, CO, N) of chemical shift assignments for a given protein sequence (48). The 
method relies on the fact that the phi and psi of the different nuclei in the protein 
backbone are related both to the type of amino acid and to the nature of the 
secondary structure they are located in. 
 
2.5. Collection of conformational constraints 
For use in structure calculation, geometric conformational information in the 
form of distances and/or torsion angles has to be derived from the NMR data. The 
latter have to be supplemented by information about the covalent structure of the 
protein, such as the amino acid sequence, bond lengths, bond angles, chiralities, and 
planar groups, as well as by steric repulsion between non-bonded atom pairs. 
Although a variety of NMR parameters contain structural information, the crucial 
information comes from NOE measurements which provide distance information 
between pairs of protons. Supplementary constraints can be derived from through 
bond correlations in the form of dihedral angles (39). Further, CSI data, provides, as 
before mentioned, information on the type of secondary structure. Such information 
can be included in a structure calculation by restricting the local conformation of a 
residue to the helical or -sheet regions of the Ramachandran plot through torsion 
angle restraints. Furthermore, hydrogen bonds can be experimentally detected via 
through-bond interactions (49) and they can be useful during structure calculations of 
larger proteins when not enough NOE data are available yet. Few years ago a new 
class of conformational restraints has been introduced that originates from residual 
dipolar couplings (RDC) in partially aligned or paramagnetic molecules and gives 
information on angles between covalent bonds and globally defined axes in the 
molecule, namely those of the magnetic susceptibility tensor (50, 51). 
The intensity of a NOE, i.e. the volume V of the corresponding cross peak in a 
NOESY spectrum (17,18)(52), is related to the distance r between the two interacting 
spins by:  
V=<r-6>f (c)      (1) 
NOEs are usually treated as upper inter-atomic distance rather than as precise 
distance restraints. Adding the information on the distance between pairs of protons 
and their position in the polypeptide sequence allows construction of possible 
arrangements in which all distance constraints are fulfilled. 
Of particularly utility for the NMR structure determination are scalar three-bond 
3JHX coupling constants. The magnitude of these constants is related to dihedral 
angles subtended by the covalent bonds that connect the coupled nuclei H and X, 
where X can be 1H, 15N or 13C. According to Karplus (53), the dependence of the 
three-bond J coupling constant on the dihedral angle  subtended by the three 
successive covalent bonds that connect the coupled nuclei is embodied in the 
relation: 
 
3J() = A cos2() + B cos() + C     (2) 
where  = torsion angle (, ,  etc); A, B and C are Karplus constants depending on 
the type of the torsion angle. 3JHNH coupling constants ( torsion angle) are obtained 
from the ratio between the intensity of the diagonal peak and that of the cross-peak 
of the HNHA map. Through the analysis of the HNHB spectrum the 3JHNH coupling 
constants ( torsion angles) can be derived. The process of defining useful 
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conformational constraints on the basis of J coupling constants usually requires the 
translation of these quantities into molecular-geometry related dihedral-angle values. 
 
2.6. Structure calculation, refinement and validation 
Using NMR constrains, calculation programs fold a random generated 3D 
structure, in order to maximize the agreement between the structure and the 
structural constraints. A NMR structure is represented by a family of conformers 
which are in good agreement with the structural constraints imposed. The precision 
of the structure is measured by the root-mean-square-deviation (RMSD) of the 
coordinates of the protein atoms for each conformer of the family from the mean 
structure and the accuracy of the structure is measured by an average target function 
of the family; the latter measures the agreement between the structure and the given 
set of constraints. 
Starting from chemical shifts and NOESY spectra all the calculation works 
have been done with the software UNIO based on the programs ATNOS-CANDID 
(54, 55) coupled with CYANA-2.1 (56) by using torsion angle dynamics algorithm. In 
this algorithm, the molecular dynamics simulation uses torsion angles as degree of 
freedom, while bond lengths, angles, and backbone peptide plane angles are fixed. 
In particular, ATNOS/CANDID program, based on the backbone and side-chains 
assignment, allows obtaining the automated NOESY peak picking (ATNOS) and the 
automated NOE assignment (CANDID). During the integration time steps, the best 
conformations were searched by minimized the deviation between the constraints 
and obtained conformations. Compared with other algorithms, torsion angle 
dynamics provides at present the most efficient way to calculate NMR structures. 
At the end of the structure calculation, an important question is if the structure 
calculation was ―successful‖. There are two important features, i) whether the 
calculated structures fulfil the given restraints, ii) whether the calculations are 
converged. The first feature could be described by statistical report of the target 
function. In each calculation, 20 or 30 conformers, among 200 or 350 conformers, 
with lowest final target functions were chosen to represent the solution structures. 
The average values of target function of the represent structures should be smaller 
than 1Å2 and each single violation should be smaller than 0.3 Å2. The second feature 
was judged by RMSD between these models. Only the family structure with 
backbone RMSD values close or less than 1 Å will be considered as ―good‖. The 
―good‖ structures obtained from torsion angle dynamics finally will be refined in 
AMBER program (57). In the final refinement, force field parameters are also 
considered. The refinement in explicit water box after the refinement in vacuum make 
the structure qualities further improved. 
The solved structures could be flawed or present a wrong fold, even if RMSD 
and target function values are accepted. The defect could be induced by only a few 
wrong assigned NOEs or other local constraints. 
The validation package provides a tool to understand the quality of the 
structures. In this thesis, the software iCING based on the programs 
PROCHEK_NMR, WHATIF and QUEEN (58-60) was used for judging the structure 
quality. The solution structures will be accepted if more than 90% residues fall into 
the allowed region of Ramachandran plot and less than 1% residues in the 
disallowed region. 
PROCHEK_NMR provides a detailed check on the stereochemistry of a 
protein structure, while WHATIF try to assess the quality of a structure primarily by 
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checking whether a number of different parameters are in agreement with their 
values in databases derived from high-resolution X-ray structures. 
QUEEN (QUantitative Evaluation of Experimental Nmr restraints) is a method 
which describes the quantitative evaluation of experimental NMR restraints. This 
method successfully identifies the crucial restraints in a structure determination: 
those restraints that are both important and unique. 
 
2.7. 15N relaxation in proteins 
Protein mobility has an increasing relevance to our understanding of biological 
and chemical phenomena for the recognized importance of protein internal motions 
in biological processes. Macromolecular functions are often associated to energetic 
transition, which are intimately connected with structural changes and molecular 
flexibility. The measurement of 15N relaxation rates in isotopically enriched proteins is 
particularly useful for obtaining dynamics information since the relaxation of this 
nucleus is governed predominantly by the dipolar interaction with directly bound 
proton and by the chemical shift anisotropy (CSA) mechanism. 
In a 15N relaxation experiment, one creates a non-equilibrium spin order and 
records how this relaxes back to equilibrium. At equilibrium, the 15N magnetization is 
aligned along the external field, and this alignment can be changed by radio 
frequency pulses. The magnetization will relax back to equilibrium along the direction 
of the magnetic filed with a constant time called longitudinal relaxation time T1. When 
outside equilibrium the magnetization can have also a component perpendicular to 
the external magnetic field. The time constant for this spin component to return to 
equilibrium is called transverse relaxation time, T2. A third source of relaxation 
parameter is the heteronuclear NOE. This is measured by saturating the proton (1H) 
signal and observing changes in the 15N signal intensities. 
The relaxation parameters are related to the spectral density function, of the 
1H-15N bond vector by the following equations (61, 62): 
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in which d=(0hNH/8r
3
NH) and c=NN/3. Rex is a term introduced to account for 
microsecond to millisecond conformational exchange contributions to R2. 
The dynamic information contained in the relaxation rates are represented by 
the values of the spectral density function, J(), at several frequencies. The 
descriptions of the dynamics require therefore the identification of a suitable model 
30 
 
for the spectral density function, which must be consistent with the experimental 
relaxation rates. The spectral density is often expressed in terms of global tumbling 
parameters, and of local motional parameters.  
 
2.8. Data Analysis 
2.8.1. Spectra Density Mapping 
The spectral density mapping approach was developed by Peng and Wagner 
in 1992 (63). It makes use of six different relaxation parameters, which are used to 
map the spectral density function. These parameters are: 1) the longitudinal 15N 
relaxation rate, R1, 2) the transverse 
15N relaxation rate, R2, 3) the 
1H→15N 
heteronuclear NOE, 4) the relaxation rate of longitudinal two-spin order RNH(2HzNz), 
5) the relaxation rate of anti-phase 15N coherence RNH(2HzNx,y) and 6) longitudinal 
relaxation of the amide protons. The method of spectral density mapping does not 
require any assumption regarding the form of the spectral density functions. Values 
of the spectral density functions of 1H-15N vectors are directly sampled at several 
relevant frequencies (e.g. 0, H-N, H+N, H, N). Drawbacks in this method reside 
in the fact that the three measurable relaxation parameters, R1, R2 and heteronuclear 
NOE, are insufficient to determine uniquely the values of the spectral density function 
at the five frequencies in equations (1) to (3) and that anomalous behaviour can be 
expected for the spectral densities at the three highest frequencies (63). These 
problems can be overcome by a more recent approach called reduced spectral 
density mapping, in which the values of the spectral density function at H-N, H+N 
and H frequencies can be combined in a average spectral density <J(H)> (64, 65). 
A comparison of J() measured at high and low frequencies provides a quantitative 
measure of the breadth of the frequency distribution accessed through the spatial 
fluctuations of the bond and the overall tumbling of the molecule. 
 
2.8.2. Model Free Approach 
A different method, called Model Free approach, has been introduced by 
Lipari and Szabo (66). This model assumes that the overall rotation of the molecule 
can be described by a single correlation time (isotropic motion) and that this overall 
motion and the internal motions are independent. Then the total correlation function 
can be factored as:  
C(t)= CO(t) CI(t)     (6) 
 
where C(t) is the total correlation function, CO(t) is the correlation function 
characterizing  the overall rotation and CI(t) is the correlation function characterizing 
the internal motions. 
As a consequence, the global spectral density function can be expressed as a 
weighted sum of Lorentzian functions. This is correct rigorously for isotropic rotational 
diffusion and approximately for anisotropic rotational diffusion. 
The Lipari and Szabo formalism employs a minimum number of parameters to 
describe the overall isotropic tumbling motion of a macromolecule and the internal 
motions of the 15N-1H bond vector. The central equation in the Model Free Approach 
is:  
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where m is the correlation time as a result of the isotropic tumbling motion of the 
entire molecule. The effective correlation time resulting from internal motions is 
described by e, where  
-1 = m
-1 + e
-1. The order parameter S2 describes the degree 
of spatial restriction of the internal motion of the 1H-15N bond vector. It satisfies the 
inequality 0  S  1 and lower values indicate larger amplitudes of internal motions. 
As a consequence, for a nucleus rotating as a whole with the molecule, all 
contributions to the spectral density function derive from the overall tumbling; 
alternatively, extra contributions will be described by other motions with correlation 
times faster than the overall tumbling. An extended form of the model-free spectral 
density function has been developed by Clore and co-workers (67) to describe 
internal motions that take place on two distinct time scales, differing by at least an 
order of magnitude. 
 
2.9. The contribution to relaxation of exchange processes  
The presence of exchange processes occurring in the micro-millisecond time 
scale produces dephasing of magnetization and contributes to make the transverse 
relaxation time shorter. A method to obtain a detailed analysis of exchange 
contribution is the measurement of R2 rates as a function of the refocusing times 
CPMG(=1/(2CPMG), where CPMG is the frequency of repetition of 180° pulses during 
the Carr-Purcell-Meiboom-Gill (CPMG) sequence (68). The contribution of the 
exchange processes (Rex) to the transverse relaxation rate can be expressed as 
follow (69): 
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where  = ( kex
2 – 4pApB
2)1/2 , kex = 1/ex and  eff(s
-1

1
2(T  CPMG)  
pA and pB are the populations of the sites A and B in a two-site exchange process,  
is the difference of Larmor frequencies between the sites and ex is the time constant 
for the exchange process.  
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3.1. Introduction 
Streptococcus pneumoniae is an important human pathogen responsible for 
diseases such as otitis media, pneumonia, sepsis meningitis (70-75). However, S. 
pneumoniae is also a common inhabitant of the respiratory tract of children and 
healthy adults. This carriage state could represent a risk factor for the development 
of respiratory diseases but also the source for pneumococcal transmission to other 
individuals (76-78). Like most streptococci, S. pneumoniae decorates its surface with 
long filaments known as pili (23, 79-82). Pneumococcal pili have previously been 
associated with virulence and the capability of the microorganism to adhere better to 
epithelial cells and to colonize the nasopharynx (23, 24, 83).  
The pneumococcal pilus is a multimeric structure consisting of three proteins 
(RrgA, RrgB, and RrgC) polymerized by three sortase enzymes (SrtC1, SrtC2, and 
SrtC3) through the formation of covalent intermolecular isopeptide bonds (25, 84-87). 
In particular, multiple copies of RrgB are polymerized to form the scaffold of the pilus, 
whereas the major adhesin, RrgA, and the putative anchor, RrgC, are localized at the 
tip and at the base of the pilus, respectively (24, 88, 89). Recently, the structure of a 
major portion of RrgB (residues 184–627) was solved at a 1.6 Å resolution (90) and 
revealed an organization into three independently folded IgG-like domains (D2, D3, 
and D4, residues 184–326, 326–446, and 446–627, respectively). On the contrary, 
the structure of the RrgB N-terminal region (D1, residues 1–184), likely constituting a 
fourth independently folded domain, remained unsolved due to the failure to obtain 
the crystals of the full-length (FL) RrgB (90). Interestingly, each of the D2, D3, and 
D4 domains is stabilized by one intramolecular isopeptide bond. These covalent 
linkages, formed between Lys and Asn residues, have been found in other pilus 
proteins (86, 91-94) and are thought to play a role similar to that of disulfide bonds; 
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they confer in fact a rigid molecular architecture to the pili and make them less 
susceptible to proteolytic cleavage (Fig. 1). 
 
 
 
Figure 1. Schematic representation of pilus backbone protein RrgB. Pilus scaffold is composed by multiples copies of RrgB 
protein in a head-to-tail arrangement. Pilus polymerization occurs through intermolecular isopeptide bonds (red), whereas each 
RrgB protein is stabilized by intramolecular isopeptide bonds (black). Lys-183 as a residue involved in the intermolecular bond 
has been identified in the present work. 
 
In the pilus backbone assembly RrgB molecules are linked together by 
sortases through intermolecular isopeptide bond formation between a Thr within the 
C-terminal LPXTG motif of a molecule and a Lys located at the N terminus of the 
following molecule (85, 94, 95) (Fig. 1). In Corynebacterium diphtheriae, where the 
general principles of pilus assembly were first established, the functional Lys is 
located within a conserved YPKN ―pilin‖ motif (85, 92, 96). Nevertheless, this 
sequence is not absolutely required for polymerization as demonstrated by studies 
on the Spy0128 pilin of Streptococcus pyogenes, where the lysine forming the 
intermolecular isopeptide bond and responsible for pilus polymerization is located 
into 159GSKVPI164 motif even though the YPKN pilin motif is also present (94, 97). 
RrgB, along with the other two pilus proteins RrgA and RrgC, was previously 
shown to confer protection in mouse models of infection and therefore is regarded as 
a potential candidate for a new generation of protein-based vaccines (26, 98). We 
have investigated the protective ability of the single recombinant D1, D2, D3, and D4 
domains of RrgB in a mouse model of sepsis, and here we provide evidence that D1 
is the most protective, followed by D4. 
Furthermore, we present the solution structure of the recombinant D1 obtained 
by NMR spectroscopy and show that Lys-183 of D1 is engaged in the intermolecular 
isopeptide bond formation during pilus polymerization. Finally, we propose a possible 
model of the entire RrgB molecule and show the positions of two linear epitopes 
possibly involved in the protection mechanism. 
 
3.2. Material and Methods 
Bacterial Strains and Cultures- For the animal experiments, the S. pneumoniae 
TIGR4 (serotype 4) strain was used. Bacteria were grown, frozen in aliquots at －80 
°C, and titrated as already reported (26). Immediately prior to challenge, frozen 
aliquots were thawed and diluted in PBS to reach the working concentration. 
Cloning and Protein Expression and Purification- Standard recombinant DNA 
techniques were used to construct the expression plasmids (pET21b+; Novagen) and 
to express and purify the recombinant C-terminal His-tagged proteins. The affinity-
purified proteins were subsequently used to immunize CD1 mice or rabbits for 
antibody generation (Charles River Laboratory) and BALB/c mice to evaluate the 
protective efficacy. 
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Complementation Plasmids- Wild-type or mutant rrgB genes were amplified from 
chromosomal DNA of TIGR4 strain by PCR. Point mutations were introduced by 
overlap extension PCR by using specific primers. PCR products were then cloned 
into the complementation plasmid pMU1328 between the BamHI and SalI restriction 
sites (26). Expression of RrgB or RrgB mutated forms was under control of the 
erythromycin constitutive promoter (Pc) which was amplified with the specific and 
cloned immediately upstream rrgB (EcoRI, BamHI). All plasmids were confirmed by 
sequencing. 
Generation of rrgB Deletion Mutants and rrgB Complementants- A TIGR4 rrgB 
isogenic mutant was generated by allelic exchange. Fragments of ~500 bp upstream 
and downstream the target gene were amplified by and spliced into a kanamycin 
resistance cassette by using overlap extension PCR; the PCR fragments were then 
cloned into pGEMt (Promega) and transformed in S. pneumoniae with conventional 
methods (99). To select the bacteria in which the target gene was replaced with the 
resistance cassette, bacteria were plated on blood-agar plates with kanamycin (500 
µg/ml). The presence of the isogenic mutation was confirmed by PCR and Western 
blot (WB) analysis. To obtain RrgB-complemented mutants, pMU1328 plasmids 
containing WT rrgB or rrgB mutated forms were transformed into TIGR4 ΔrrgB with 
conventional methods. Transformants selection was performed by supplementing 
media with kanamycin (500 µg/ml) and erythromycin (1 µg/ml). The complemented 
mutants were then analyzed by PCR; expression of FL WT RrgB or RrgB mutants 
was detected by WB analysis of whole cell lysates. 
SDS-PAGE and Western Blot Analysis- SDS-PAGE analysis was performed using 
NuPAGE TM 4–12% BisTris gradient gels (Invitrogen) according to the 
manufacturer‘s instructions. Hi-MarkTM prestained HMW (Invitrogen) served as 
protein standard. Gels were processed for WB analysis by using standard protocols. 
Mouse polyclonal antibodies raised against recombinant His-tagged RrgB were used 
at 1/3000 dilution. Secondary goat anti-mouse IgG alkaline phosphatase-conjugated 
antibodies (Promega) were used at 1/5000, and signals were developed by using 
Western Blue Stabilized Substrate for Alkaline Phosphatase (Promega). 
Animal Experiments- Animal studies were done in compliance with the current law 
approved by the local Animal Ethics Committee and authorized by the Italian Ministry 
of Health. Female, 6-week-old, specific pathogen-free BALB/c mice (Charles River) 
received three intraperitoneal immunizations, 2 weeks apart. Each dose was 
composed of 20 µg of either the single RrgB domains or the FL RrgB, or of a 
combination of the four RrgB domains (D1+D2+D3+D4), 10 µg each, along with 
400µg of aluminum hydroxide as an adjuvant, in a final volume of 200 µl of PBS. 
Control animals received the same course of saline plus adjuvant. Ten days after the 
third immunization, samples of sera were obtained from each animal and pooled 
according to the immunization group to be used in passive serum transfer 
experiment. Two weeks after the third immunization, each mouse was challenged 
intraperitoneally with a mean dose of 1.6x102 cfu of TIGR4. Bacteremia was 
evaluated 24 h after challenge, and mortality course monitored for 10 days after 
challenge as already reported (26). The animals were euthanized when they 
exhibited defined humane end points that had been pre-established for the study in 
agreement with Novartis Animal Welfare Policies. For passive protection 
experiments, 8-week-old mice were used. Fifteen minutes before TIGR4 
intraperitoneal challenge (102 cfu/mouse), each mouse received intraperitoneally 
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50µl of pooled mouse sera against recombinant D1 or D4, or of control sera obtained 
immunizing with adjuvant plus saline. 
Statistical Analysis- Bacteremia and mortality course were analyzed by the Mann-
Whitney U test. Survival rates were analyzed by Fisher‘s exact test. One-tailed or 
two-tailed tests were used to compare immunized groups with the control group or 
each other, respectively. Values of p ≤0.05 were considered and referred to as 
significant. Values of p ≤ 0.1 were referred to as a trend. 
Flow Cytometry on Entire Bacteria- TIGR4 were grown in Todd-Hewitt yeast 
extract broth to an exponential phase (A600 = 0.25), fixed with 2% formaldehyde, and 
then stained with pooled mouse antisera raised against FL RrgB or RrgB domains at 
1:400 dilution. Mouse IgG were detected with FITC-conjugated goat anti-mouse IgG 
(Jackson Laboratories) at 1:100 dilution, and bacterial staining was analyzed by 
using a FACS-Calibur cytometer (Becton Dickinson). Sera from mice immunized with 
PBS plus adjuvant were used as negative control. 
ELISA- 96-well MaxiSorpTM flat-bottom plates (Nunc) were coated with 0.2 µg/well 
FL RrgB overnight at 4 °C. Plates were then washed three times with PBS/0.05% 
Tween 20 and saturated for 1 h at 37 °C with PBS/1% BSA. Following three washing 
steps with PBS/0.05% Tween 20, the plates were incubated for 2 h at 37 °C with 
serial dilutions of the pooled mouse sera. After another three washing steps, bound 
antigen-specific mouse IgGs were revealed with alkaline phosphatase-conjugated 
goat anti-mouse IgG (Sigma), followed by the phosphatase alkaline substrate p-
nitrophenyl phosphate (Sigma). The intensity of color was quantified with an ELISA 
plate reader at A405. The antibody titer was expressed as the log10 of the reciprocal 
of the serum dilution that gave A405 = 1. 
PepScan Analysis- Arrayed peptides were synthesized in situ on glass fiber 
membranes. Membranes were conditioned by wetting with ethanol and washing 
three times for 5 min in TTBS (50 mM Tris-HCl, pH 7.0, 137 mM NaCl, 2.7 mM KCl, 
0.05% Tween 20). After overnight blocking at 4 °C in MBS (2% dry milk in TTBS), 
membranes were incubated for 1.5 h at 37 °C with polyclonal antisera (1:3000 in 
MBS) followed by secondary goat anti-mouse IgG alkaline phosphatase-conjugated 
antibodies (1:5000 in MBS; Promega), and signals were developed by using Western 
Blue Stabilized Substrate for Alkaline Phosphatase. For image processing, 
membranes were scanned using an Epson V750 Pro scanner at 800 dpi, 48-bit color 
depth and with gamma 1.0 full linear response. 
NMR Characterization of RrgB D1 Domain- NMR spectra were acquired at 298 K 
on Avance 900, 800, 700, and 500 MHz Bruker spectrometers, all equipped with a 
triple resonance cryoprobe. The NMR experiments, used for the backbone and the 
aliphatic side chain resonances assignment recorded on 13C/15N and 15N enriched 
samples or on unlabeled D1 samples, are summarized in Table 1. Backbone dihedral 
angle constraints were derived from 15N, 13C‘, 13Cα, 13Cα, and Hα chemical shifts, 
using TALOS+ (100). Distance constraints for structure determination were obtained 
from 15N-edited and 13C-edited three-dimensional NOESY-HSQC. 3131 meaningful 
proton-proton distance restraints (Table 1), with 114 φ and 120 ψ backbone dihedral 
angles restraints were included in structure calculations.  
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Experiments 
b 
Dimension of acquired data Spectral width n
a 
(nucleus) (ppm) 
       t1                   t2                      t3      F1          F2              F3   
[
1
H-
1
H]-NOESY 
c 
  1024(
1
H) 2048(
1
H)  16 16   32 
[
1
H-
1
H]-TOCSY 
c
   1024(
1
H) 2048(
1
H)  16 16   32 
1
H-
15
N-HSQC 128(
15
N) 1024(
1
H)  36 14   8 
1
H-
13
C-HSQC 128(
13
C) 2048(
1
H)  80 14   8 
 trhncocacb 
d 
96(
13
C) 56(
15
N) 2048(
1
H) 80 36 14 8 
 trhncacb 
d 
96(
13
C) 56(
15
N) 2048(
1
H) 80 36 14 8 
 trhnco 
d 
96(
13
C) 56(
15
N) 1024(
1
H) 36 36 14 16 
 trhncaco 
d 
96(
13
C) 56(
15
N) 1024(
1
H) 36 36 14 24 
trhnca 
d 
96(
13
C) 56(
15
N) 2048(
1
H) 42 36 14 8 
trhncoca 
d 
96(
13
C) 56(
15
N) 2048(
1
H) 42 36 14 16 
Hbhaconh 88(
1
H) 52(
15
N) 1024(
1
H) 12 36 12 8 
(H)CCH-TOCSY
  
224(
13
C) 56(
13
C)     2048(
1
H) 14 36 14 16 
15
N-edited [
1
H-
1
H]-NOESY 256(
1
H) 56(
15
N)     1024(
1
H) 14 36 14 16 
13
C-edited [
1
H-
1
H]-NOESY  248(
1
H) 104(
13
C) 1024(
1
H) 14 24 14 8 
2
J-HSQC 
e 
128(
1
H)  1024(
1
H)  170 20  48 
15
N R1 
f
  160(
15
N) 1024(
1
H)  38 14  16 
15
N R2
 f 
160(
15
N) 1024(
1
H)  38 14  16 
1
H-
15
N NOE
 f 
320(
15
N) 1024(
1
H)  38 14  32 
a 
number of acquired scans. 
b 
All the experiments were acquired on a 500, 700, 800 and 900 MHz 
spectrometer equipped with a triple resonance cryoprobe at 298 K. All the triple resonance (TXI 5-mm) 
probes used were equipped with Pulsed Field Gradients along the z-axis. 
c 
The experiment  was acquired in 
D2O for the assignment of the aromatic protons, the spectra analysis provided the assignment of the side 
chain of aromatic residues. 
d 
The experiments  were acquired on 
13
C/
15
N enriched D1 sample. 
e 
Histidine 
coordination mode was determined through 
1
H-
15
N heteronuclear experiments to detect the 
2
J 
1
H-
15
N 
coupling between the imidazole nitrogens and non exchangeable imidazole protons. 
f 
The 
15
N longitudinal relaxation rates, R1, were measured using delays in the pulse sequence of 2.5, 35, 75, 
125, 200, 350, 500, 750, 1000, 1500, 2000 and 3000 ms for all samples. The 
15
N transverse relaxation rates, 
R2, were measured using the CPMG sequence. The relaxation delays used were 16.96, 33.92, 50.88, 84.80, 
118.72, 152.64, 186.56, 220.48, 254.40 and 288.32 ms. The interscan delay (d1) was 3 s for R1 and R2 and 5 
s for 
1
H-
15
N NOE respectively.  R1 and R2 relaxation rates were obtained by fitting the cross peak volumes (I), 
measured as a function of the relaxation delay, to a single exponential decay as described in the literature. 
Heteronuclear NOE values were calculated as the ratio of peak volumes in spectra recorded with and without 
saturation. In all experiments the water signal was suppressed with the ‗water flipback‘ scheme. All 3D and 
2D spectra were processed using the standard Bruker software TOPSPIN and analyzed through CARA and 
XEASY programs. 
Table 1. Acquisition parameters for NMR experiments performed on D1 domain 
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The exchangeability of the backbone amide hydrogen nuclei with solvent protons 
was investigated through a 1H-15N HSQC experiment performed on a protein sample 
dialyzed against deuterated buffer for 3 days. Hydrogen bond constraints for the 
slowly deuterium-exchanging amide protons of the β-strands were introduced at later 
steps of the structure calculations. Structure calculations were performed through 
iterative cycles of CYANA-2.1 (55) followed by restrained energy minimization with 
the AMBER 10.0 Package in explicit water solvent (57). The quality of the structures 
was evaluated by using the iCING validation program (for details, see Table 2). The 
program MOLMOL was subsequently used for structure analysis (64, 101).The final 
bundle of 20 conformers of D1 has an average target function of 1.36 ± 0.13 (CYANA 
units). The average backbone r.m.s.d. value (over residues 28–183) is 0.71 ± 0.19 Å, 
and the all-heavy atoms r.m.s.d. value is 0.96 ± 0.16 Å. Per-residue r.m.s.d. values 
are shown in Fig. 2. 
Heteronuclear Relaxation Data- The dynamic properties of D1 have been 
characterized experimentally through 15N relaxation measurements. 15N longitudinal 
and traverse relaxation rates (64) and 15N{1H} NOEs (102) were recorded at 298 K at 
500 MHz, using a protein concentration of 0.8 mM. The average backbone 15N-
longitudinal R1 and transversal R2 relaxation rates and 
15N{1H} NOE values are 1.45 
± 0.1 s-1, 16.18 ± 1.5 s-1, and 0.71 ± 0.04, respectively (Fig. 3). They are essentially 
homogeneous along the entire polypeptide sequence, with the exception of residues 
located at the C- and N-termini and three loop regions (56–69, 148–162, and 173–
177). The correlation time for the molecule tumbling (c), as estimated from the R2/R1 
ratio, is 11.49 ± 1.9 ns, consistent with the molecular mass of the monomeric protein. 
The relaxation data were analyzed according to the model-free approach of Lipari 
and Szabo (66, 103) using TENSOR2 (104)(Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. RMSD values per residue to the mean structure for the backbone (filled squares) and all heavy atoms (open 
circles) of the family of 20 conformers of D1 domain after energy minimization. The secondary structure elements are also 
reported. 
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Table 2. Statistical analysis of the energy minimized family of D1 domain conformers. 
 
RrgB D1 domain 
(20 Conformers) 
Total  number of  meaningful NOE upper distance 
constraints  
3131 
Intra-protein NOEsb 
Intra-residue 676 
Inter-residue  
      Sequential (|i-j| = 1) 801 
      Medium-range (|i-j| < 4) 450 
      Long-range (|i-j > 5) 1204 
Total meaningful dihedral angle restraints
b 
234 
      Phi 114 
      Psi 120 
RMS violations per meaningful distance constraint (Å):  
Intraresidue  0.8738±0.3661 
Sequential  0.0071±0.2822 
Medium range  0.0110±0.0011 
Long range 0.0076±0.0008 
RMS violations per meaningful dihedral angle constraints (°):  
Phi  5.9314±0.7973 
Psi  6.7689±1.6990 
Violations  
< 0.1 Å 3 
> 0.1 Å 47 
> 0.3 Å 0 
> 0.5 Å 0 
Average RMSD to the mean (Å)  
Residue range 28-183  (backbone atoms) 0.73±0.12 
Residue range 28-183  (all heavy atoms) 0.97±0.07 
Secondary structure elements (backbone atoms) 0.46±0.11 
Secondary structure elements (all heavy atoms) 0.83±0.11 
residual CYANA Target Function (Å
2
) 1.36±0.13 
Structural analysis  
% of residues in most favorable regions 83.80% 
% of residues in allowed regions 15.30% 
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% of residues in generously allowed regions 0.60% 
% of residues in disallowed regions 0.30% 
WHAT IF structure Z-scoresd  
1st generation packing quality -3.29 
2st generation packing quality -2.43 
Ramachandran plot appearance -2.85 
χ1/χ2 rotamer normality -4.94 
Backbone conformation -1.1 
WHAT IF RMS Z-scores
e 
 
Bond lengths  1.49 
Bond angles 0.82 
Omega angle restraints 1.24 
Side chain planarity 1.38 
Improper dihedral distribution 1.04 
Inside/Outside distribution 1.06 
Overall NOE completeness within 4 Å
f 
55.4 
QUEEN
f 
 
Iuni/Itotal (%) < 0.001 2481 (72.7%) 
Average/SD 0.0017 ± 0.0055 
Max  0.12 
a Structure calculations were performed with the program CYANA 2.1 (55,56). A total of 400 random 
conformers were subjected to 8000 steps of a simulated annealing process. Each member of the family 
was submitted to restrained energy minimization (REM in explicit solvent) with the Amber-10 package 
(57). Values of 50 kcal mol-1 Å-2 and 32 kcal mol-1rad-2 were used as force constants for the NOE and 
torsion angle restraints, respectively. The data are calculated over the 20 conformers representing the 
NMR structure and on the energy minimized mean structure. The mean value and the standard deviation 
are given 
b Number of meaningful constraints for each class. Backbone dihedral angle constraints were derived 
from 15N,13C’,13C,13C, and Ha chemical shifts, using TALOS and added as restrains in the structure 
calculations as well. 
c As it results from the Ramachandran plot analysis performed with CinG 
d Values calculated on secondary structure elements. A Z-score is defined as the deviation from the 
average value for this indicator observed in a database of high-resolution crystal structures, expressed in 
units of the standard deviation of this database-derived average. 
e Values calculated on all residues with iCinG 
f As it results from the analysis performed with iCinG 
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Figure 3. Experimental 
15
N R1, R2 rates and heteronuclear NOEs as obtained from the 
15
N relaxation data and 
parameters characterizing the overall and internal mobility of D1 domain within the Lipari-Szabo model. Nuclear 
relaxation rates are expressed in terms of spectral density functions J() which depend on the overall rotational correlation time, 
c, the generalized order parameter, S
2
 which describe the amplitude of local motions of backbone NHs occurring at rates faster 
than the c, and the correlation time for internal motions, e, faster than c. The secondary structure elements are reported at the 
top. The backbone amide order parameters (S
2
), the effective correlation time for motions faster than the overall tumbling rate 
(e), and the conformational exchange contribution to R2 are shown. 
Rigid Body Fitting— The procedure used to accommodate the NMR D1 structure 
into the EM map of the whole pilus previously generated (90) followed the same 
procedures used for the fitting of the RrgBD2-D4 x-ray crystal structure and the D1 
computer model into the EM pilus map (88). A preliminary rigid body fitting of the D2–
D4 crystal fragment was performed by using CHIMERA (105-107) followed by a rigid 
body fitting of the D1 NMR coordinates into the leftover N-terminal apical volume of 
the pilus. The D1 NMR coordinates were first fitted manually using CHIMERA by 
placing as much of the atomic structure as possible into the EM density map, 
approximately in the position thought to be correct. This step was then followed by a 
rigid-body fitting using the ―fit model in map‖ tool from CHIMERA. This tool 
calculates, for the selected atoms, a position that maximizes locally the sum of the 
densities. The evaluation of the correlation coefficient values, the resulting average 
map value at the fit atoms, the number of fits atoms outside the lowest value contour 
surface displayed were the parameters used to assess the fit of the D1 molecule. 
 
3.3. Results 
Distinct Domains of RrgB Provide Protection in Active Immunization 
Experiments- The protective efficacy of each of the four RrgB domains or of a 
mixture of them was assessed in a mouse model of intraperitoneal challenge 
(TIGR4) in two distinct experiments, performed under the same conditions, which 
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were combined to reach n= 13–16 mice/group. All RrgB domains except D3 afforded 
significant protection against bacteremia (Fig. 3A), giving a reduction of the cfu 
geometric mean by 1–2 logs with respect to the controls. These values were similar 
to those afforded by the FL RrgB and by the combination of the four domains 
D1+D2+D3+D4. The results of mortality are reported in Fig. D1 and D4 conferred 
significant increase of survival time, similar to FL RrgB and the combination 
D1+D2+D3+D4. In particular, the median survival for the D1 group was 2.5 days 
higher respect to that of the control group (4 versus 1.5 days). At the end of the 
mortality observation, a significant survival rate was found for D1 (44% survival), D4 
(27%), FL RrgB (44%), and D1+D2+D3+D4 (31%) groups.  
N-terminal D1 Domain Is the Most Protective in Vivo— Among the single RrgB 
domains, D1 and D4 showed the most significant protective efficacy and were 
therefore analyzed further in a larger group of mice. Four different experiments, 
carried out under the same conditions, were combined to reach n = 31 
animals/group. The results are shown in Fig. 3, C and D.  In terms of bacteremia 
(Fig. 3C), both D1 and D4 afforded highly significant protection, with a cfu geometric 
mean by 2.6 and 1.5 logs lower, respectively, than that of the control group, and 8 
animals from the D1 group in which cfu were undetectable. The reduction of 
bacteremia was significantly superior in D1 than in the D4 group. In terms of mortality 
course (Fig. 3D), both D1 and D4 conferred significant protection. The increase of 
survival time afforded by D1 showed a better trend than that of D4. 
 
 
 
 
 
 
 
 
 
Figura 3. RrgB domains are protective in active immunization experiments. 
Bacteremia (A and C): circles represent the Log CFU per ml of blood for individual 
animals; horizontal bars represent the mean value of the Log CFU/ml ± SEM for 
the group; the dotted line marks the detection limit (values under the dotted line 
correspond to animals in which no CFU were detected). The treatment groups are 
indicated on the bottom. Survival (B and D): the survival course for each group is 
represented. The treatment groups are indicated close to each of the 
corresponding survival lines. A and B: N = 13 for D2 group, 15 for D4 and control 
(alum ctrl) groups, 16 for the remaining groups; C and D: N = 31 for each of the 
groups. *** P < 0.001;** P < 0.01; * P < 0.05. 
Figura 4. Anti-RrgB D1 and D4 
sera are protective in passive 
serum transfer experiments. 
Symbols are described in the 
Figure 2 caption. N = 8 for each 
of the groups. 
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In particular, only for the D1 group was the median survival time higher than that of 
the control group (7.5 versus 1.5 days). At the end of the mortality observation, the 
D1 group showed the highest survival rate, i.e. 45% versus 21% observed for D4. An 
evident difference of survival rates between D1 and D4 groups was observed. The 
possible relevance of antibodies in the protection elicited by D1 and D4 was 
investigated by a passive serum transfer experiment, with groups of 8 mice. 
The results are shown in Fig. 4. Both anti-D1 and anti-D4 sera elicited significant 
protection against bacteremia (Fig. 4A), with cfu geometric means lower by 2.6 and 
1.6 logs, respectively, than that of the control group. Only anti-D1 serum afforded 
significant protection against mortality, giving 100% survival rate, whereas santi-D4 
gave a protective trend, with 60% survival rate. These results indicate that 
immunization with D1 domain and at a lower extent D4 domain, elicits functional 
antibodies that may play a role in the protection. 
 
D1 and D4 Antisera Recognize the Native Pilus and Linea Epitopes within 
RrgB—To investigate the differences in protective efficacy exerted by the isolated 
RrgB domains with respect to the FL RrgB in the in vivo assays, mouse sera were 
tested for their capability of recognizing the native pilus and the recombinant FL 
RrgB. Sera were probed against entire TIGR4 bacteria by FACS analysis. Sera 
raised against D1, D4, and D1+D2+D3+D4 gave a fluorescence intensity comparable 
with that obtained with anti-FL RrgB, whereas D2- and D3-specific antisera 
recognized the native pilus less effectively. To explain the lower recognition efficacy 
observed with D2 and D3, the same sera were titrated in ELISA against the 
recombinant FL RrgB. Antibody titers elicited by D2 and D3 immunization toward FL 
RrgB were about 10 times lower than those obtained by immunization with D1, D4, 
D1+D2+D3+D4, and FL RrgB, consistent with the results obtained by FACS analysis 
on the polymerized 
native RrgB. To gain more insights on the epitopes recognized by the protective D1 
and D4 polyclonal antibodies, a PepScan approach, suitable for identifying linear 
epitopes, was applied. Overlapping 15-mer peptides with an offset of 5 residues were 
synthesized in situ on a glass fiber membrane. The library of peptides tested covered 
residues 25–190 of D1 and 444–628 of D4. Incubation with the anti-D1 serum 
(previously used in passive protection experiments) revealed a single linear epitope 
covering residues 40–59 (D1-1) (Fig. 5B), whereas anti-D4 serum detected a unique 
linear epitope (D4-1) spanning residues 494– 508 (Fig. 5C). 
 
43 
 
 
 
Figura 5. Polyclonal antibodies raised against D1 and D4 recognize efficiently the native pilus and linear epitopes 
within RrgB. A) TIGR4 bacteria were incubated with mouse primary antibodies directed against the specified recombinant 
proteins (1:400 dilution), followed by FITC-conjugated goat anti mouse IgG (1:100 dilution). Bacterial staining was analyzed by 
flow cytometry (FACS-Calibur). Mouse control sera (immunized with PBS plus alum) were used as negative control. B-C) Glass 
fiber membranes with arrayed peptides synthesized in situ covering residues 25 to 190 (D1) and 444 to 628 (D4) of RrgB were 
incubated with anti-D1 (A) or -D4 (B) polyclonal mouse antibodies (1:3000), and then with goat anti-mouse IgG alkaline 
phosphatase-conjugated antibodies (1:5000). Linear epitopes corresponding to peptide sequences recognized by the antibodies 
are reported. Underlining marks common residues present in peptides adjacent in the PepScan 
 
Solution Structure of the D1 Domain—The solution structure of D1 was 
investigated by NMR spectroscopy. Its 1H-15NHSQC spectrum showed well 
dispersed resonances indicative of an overall well folded protein (Fig. 6). D1 showed 
a common IgG-like β sandwich fold (41 Å x 48 Å x 30 Å) and a topology of secondary 
structure elements drawn in Fig. 7. The core of the structure was formed by seven 
parallel and antiparallel -strands: 1(36–39), 4(80–85), 7(119–121), 8(127–130), 
9(138–143), 10(166–169), and 11(178–180). These -strands were arranged in two 
sheets (comprising β1, β8, β11 andβ4, β7, β9, β10, respectively) packed against each 
other and flanked by two long segments (40–78, 87–117) located between strands β1 
and β4 and strands β4 and β7, respectively. An α-helix (49–57), flanked by two short β 
strands β2 (42–44) and β3 (73–75), was inserted within the first segment. Two 
additional β-strands β5 (89–91) and β6 (97–101) formed α-hairpin structure inserted 
within the second segment. In 50% of 20 conformers of the D1 family an additional β-
sheet was formed by two short hydrogen-bonded β-strands (stretches 161–163 and 
184–187).  
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Figura 7. Solution structure of the D1 domain. A) Ribbon diagram with the secondary structure elements: β-strands are 
shown in cyan, the α-helix in red. B) Topology diagram. The α-helix is represented by a red cylinder and the β-strands are cyan 
arrows. 
 
The structure was well defined with the exception of three long loops corresponding 
to the stretches 56–69, 148–162, and 173–177 (Fig. 2). Heteronuclear relaxation 
Figure 6. 2D 15N-1H 
HSQC spectrum 
(900MHz, 298K) of D1 
domain. All the amide 
protons of the D1 
domain were assigned, 
with the exceptions of 
the first 7 residues of 
the N-terminal end and 
the last 6 residues of the 
C-terminal end and the 
residues Ile76, Glu143, 
His145, Ser146, 
Ser148,Thr149, 
Tyr150,Val152 and 
Gly160. 
15N(ppm) 
1H(ppm) 
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measurements revealed that residues in the first two loops had heteronuclear NOE 
and longitudinal R1 values lower and higher than average, respectively (Fig. 3). This 
behavior was a consequence of local internal motions occurring on a faster time 
scale with respect to the overall reorientational correlation time (r) of the molecule 
and accordingly, a correlation time (e) for these fast motions can be fitted for the 
previous mentioned loops ( Fig. 3). In addition, conformational exchange processes, 
occurring on the millisecond- microsecond scale, affected some residues located in 
the region 155–164, as monitored by transverse R2 relaxation rates higher than the 
average (Fig. 3). These data indicated that these loops experience higher flexibility, 
showing accordingly a low number of long ranges 1H-1H NOEs. For a few residues, 
the assignment of the backbone resonances was also not achieved (Glu-143, His-
145, Ser- 146, Ser-148, Thr-149, Tyr-150, Val-152, and Gly-160), likely as a 
consequence of an increased local mobility. The loop between strands β9 and β10 
(residues 148–162) was the most disordered, with a r.m.s.d. value of about 2 Å ( Fig. 
2). Conformational exchange processes on the millisecond-microsecond time scale 
are observed also for the loop between strands β10 and β11 comprising residues 174–
178. The protein core is characterized by hydrophobic interactions between residues 
located on the first (strands β1, β8, β11) and second (strands β4, β7, β9, β10) sheets. A 
salt bridge between two complementarily charged side chains of residues Lys-41 and 
Glu-143 was also present. The aliphatic side chains of residues Met-48, Ile-52, Ala-
53, and Leu-56, all located on one side of the α-helix, formed hydrophobic 
interactions with aliphatic residues of β2 and β3 strands; these interactions 
determined the position of the helix with respect to the rest of the protein. A search 
for related protein structures performed through the DALI server (108) retrieved the 
N-terminal domain of the SpaA pilus backbone protein of C. diphtheriae (Protein Data 
Bank (PDB) code 3HTL; r.m.s.d. 2.1 Å), the C-terminal CNA3 domain of the major 
pilin protein of Bacillus cereus BcpA (PDB code 3KPT; r.m.s.d. 2.4 Å), and the N1 
domain of the Streptococcus agalactiae minor pilin GBS52 (PDB code 2PZ4; r.m.s.d. 
3.4 Å). Like D1, none of these domains contained intramolecular isopeptide bonds. 
However, only the SpaA domain is located at theNterminus of pilus backbone protein 
as D1; their overlay is presented in Fig. 6A. In an attempt to determine the orientation 
of D1 with respect to the D2–D4 RrgB portion, a rigid body fitting of all the domains 
into the shape of the native pilus obtained from crio-electron microscopy (cryo-EM) 
was attempted (90). Initial rigid body fitting of the D2–D4 crystal structure into the 
cryo-EM density map of the native pilus left an apical unoccupied volume, likely due 
to the absence of D1. However, when the simultaneous fitting of the D1 and the D2–
D4 domains was carried out, some portions of D1 could not be accommodated into 
the apical empty volume. To model the FL RrgB, we merged the D1 and D2–D4 
structures into a single molecule by overlapping residues 188–191, shared by the C 
terminus of D1 and the N terminus of D2–D4. The relative orientation of D1 with 
respect to the others domains was then varied to best fit into the cryo-EM map (Fig. 
8). The final model, which represents only one of the possible orientations of D1 with 
respect to the rest of the protein, does not present steric clashes between D1 and the 
D2–D4 domains. The two linear epitopes, previously identified to be located within 
the D1 and D4 domains by peptide hybridization with specific protective polyclonal 
antibodies, when mapped onto the FL model of RrgB, confirmed their superficial 
localization (Fig. 8). 
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Fig. 8. Analysis of RrgB linker flexibility through superimposition and modeling. A) Superimposition of the D1 domain 
(blue) and the C. diphtheriae SpaA N-terminal domain (red). The position of Lys190 13 residue, forming the inter-molecular 
isopeptide bond between two neighboring SpaA molecules is shown along with residue Lys183 of RrgB, which occupies a 
similar position, and is indicated in a black circle. The missing loop in the SpaA crystal structure is indicated as grey dotted line. 
B) Modeled conformation of the full length RrgB molecule obtained by combining the D1 NMR coordinates with the RrgB D2-D4 
X-ray coordinates. D1_1 and D4_1 epitopes (residues 40-59 and 494-508 respectively) are rendered as yellow spheres. 
 
Lysine 183 of D1 Is Required for Intermolecular Isopeptide Bond Formation and 
Pilus Polymerization—Pili of Gram-positive bacteria are polymerized by means of 
intermolecular isopeptide bonds occurring between the Thr of the C-terminal LPXTG 
motif of a RrgB molecule and a Lys located at the N-terminus of the following 
molecule (85, 95, 96). 
To identify the Lys implicated in the intermolecular isopeptide bond formation 
between two consecutive RrgB monomers, a TIGR4 RrgB deletion mutant (no longer 
able to assemble a pilus on its surface) was created. Subsequently, RrgB expression 
and pilus polymerization were restored in TIGR4_RrgB by transforming the mutant 
with plasmids expressing either wild-type RrgB or RrgB mutated in single Lys 
residues (Lys3Ala substitutions). Sequence analysis revealed that the D1 contains 
the canonical 181YPKN184 pilin motif, with Lys-183 nicely superimposing onto the 
functional SpaA Lys-190, as shown in Fig. 8. 
Noteworthy, D1 also presents the sequence fragment 160GSKAVP165, similar to the 
motif containing the Lys residue functional for the pilus assembly in S. pyogenes 
Spy0128 (97). Lys-183 and Lys-162, along with two additional Lys residues (Lys-138 
and Lys-309), located on D1 and D3 domains, respectively, were selected and 
mutated. WB analysis performed on whole cell bacterial lysates using rabbit 
polyclonal antisera raised against RrgA, RrgB, or RrgC revealed that all of the pilus 
proteins were expressed in all of the complemented mutants. However, the typical 
pilus-associated high molecular weight ladder was revealed only in the case of 
TIGR4_RrgB complemented with RrgB wild type or RrgB mutated in Lys-162, Lys-
138, or Lys-309. In contrast, in the mutant complemented with K183A, RrgB was 
detectable only as a monomer, clearly indicating that Lys-183 is the residue 
implicated in intermolecular isopeptide bond formation. Moreover, in the presence of 
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the RrgB K183A substitution only hetero-oligomers composed of RrgA-RrgC (about 
160 kDa) or RrgB-RrgC (about 110 kDa) could be detected by WB analysis. The 
absence of RrgARrgB heterodimers suggests that RrgA and RrgB are linked 
exclusively through intermolecular isopeptide bonds involving the D1 residue Lys-183 
of RrgB. 
 
3.4. Discussion 
Ever since their initial discovery, pili of Gram-positive bacteria have received 
considerable attention because they are associated with a number of different 
virulence mechanisms (24, 83, 98), and elicit protection in animal models (26). In 
particular, the S. pneumoniae pilus was found to be implicated in the initial 
attachment to epithelial cells (24, 83, 98), and the pilus components, being protective 
in mouse models of infection, are regarded as potential vaccine candidates (26, 98). 
The major pilin RrgB is organized into four Ig-like domains (D1– D4), as shown 
by combined structural approaches approaches (90) and this work). We have tested 
the four RrgB domains in animal model experiments and have shown that the 
protective efficacy exerted by the combination of the four RrgB domains 
D1+D2+D3+D4 is comparable with that afforded by the FL RrgB. Among the single 
domains, D1 is the most protective, and D4 retained an important part of the 
protective efficacy of the FL protein. The lower protection achieved by D2 and D3 
compared with the FL protein, as well as with the D1 and D4, is probably because 
the antibodies elicited by the former two domains recognize the FL protein less 
efficiently, in both its native and recombinant forms. This may be the result of smaller 
exposed surface areas experienced by D2 and D3 in the FL RrgB compared with the 
D2 and D3 isolated domains and with D1 and D4. It is possible, in fact, that the 
antibodies generated against the isolated domains are recognizing areas of D2 and 
D3 that are buried in the FL protein. Alternatively, D2 and D3 could assume a slightly 
different conformation when expressed as single domains, thus generating 
nonfunctional antibodies. On the other hand, the two linear epitopes (Fig. 8) identified 
within D1 and D4 by PepScan analysis performed with protective polyclonal 
antibodies raised against the two domains (conformational epitopes are not 
detectable with this method) are well exposed on the surface of the RrgB molecule 
and could contribute to the protective activity exerted by D1 and D4. Further 
experiments are needed to understand to what extent these linear epitopes 
contribute to the protective activity exerted by the two domains. Taken together, 
these results suggest that RrgB contains multiple protective epitopes, thus confirming 
the potential of this vaccine candidate. Furthermore, although the existence of 
possible conformational epitopes involving residues from different domains cannot be 
excluded, their contribution to the overall protective efficacy might not be essential. 
To obtain more information about the structural role of D1 and to try to 
correlate it with the protection data discussed above, we solved the solution structure 
of this domain by using NMR spectroscopy. D1 shows an Ig-like fold, does not 
contain any intramolecular isopeptide bond, and has many flexible regions. The 
observed D1 flexibility, indeed, could play a fundamental role in the specific antigen-
antibody recognition process (109), thus accounting for D1 enhanced protection 
capability with respect to the more rigid D2–D4 domains, each one containing an 
intramolecular isopeptide bond. In fact, the protein structural plasticity could be 
related to the ability of D1 to undergo local conformational changes and to adapt its 
structure to optimize the interactions with the antibodies and increase the affinity and 
the specificity of the antigen-antibody recognition process. The dynamics of D1 could 
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therefore strongly contribute to the interface adaptation for molecular recognition 
such that the antibody can select an optimal conformer from a wide distribution of 
possible D1 conformations. The rigid structure of the D2–D4 region prevents such an 
effective conformational selection for these domains. The above described 
phenomenon has been observed for other protein-protein or protein-DNA interaction 
processes (109, 110). To shed light on the molecular mechanism driving pilus 
polymerization in S. pneumoniae, we investigated which of the lysine residues of D1 
was engaged in the intermolecular isopeptide bond formation. Site-directed 
mutagenesis followed by complementation identified Lys-183 as crucial for the pilus 
assembly. This result is consistent with the observation that the spatial position of 
RrgB Lys-183 can be superimposed onto Lys- 190 of the C. diphtheriae pilus 
backbone subunit SpaA, known to be involved in the intermolecular isopeptide 
linkage (96). Interestingly, as shown in Fig. 8, both lysines are not fully available to 
form an external bond. In particular, the average relative solvent accessibility of the 
Lys-183 over the D1 family of conformers is 27.2% ± 4.8, as the Lys side chain 
projects into a cleft between the main body of the protein and the segment 40–78 
containing the mobile loop 56–69 (92). This suggests that pilus backbone proteins, to 
be polymerized, might undergo conformational changes, probably involving not only 
the Lys residue (Lys-183) but also the flexible regions spatially close to it (49–69, 
152–167, and 183–193), to allow the formation of the covalent intermolecular 
isopeptide bond. NMR mobility data indicate that the C terminus of the D1, where 
Lys-183 is located, and other loops are highly mobile and that such dynamics could 
be relevant for the intermolecular isopeptide bond formation (Figura 3). Consistently, 
the absence of stabilizing intramolecular isopeptide bonds renders D1, unlike the 
other domains, less rigid and prone to conformational rearrangements. 
 Furthermore, the occurrence of a structural rearrangement of D1 within the 
native pilus structure is also in line with the partial fitting of its NMR structure onto the 
molecular shape of the native pilus determined by cryo-EM. Mutagenesis and 
complementation data were used to analyze the covalent links established among 
the three pilus proteins either in the absence of RrgB or in the presence of the RrgB 
K183A mutant, in an attempt to provide further insights into the possible organization 
of the native pilus. In the presence of the non polymerizing RrgB K183A mutant, the 
lack of RrgA-RrgB heterodimers provides evidence that RrgA and RrgB are 
unidirectionally linked only through the Lys-183 of RrgB and the C-terminal Thr of 
RrgA. This arrangement is in accordance with the model proposed by Hilleringmann 
et al., positioning RrgA at the pilus terminus, thus ruling out the alternative possibility 
of RrgA being incorporated along the pilus shaft (88). Conversely, an RrgA-RrgC 
multimer is detectable either when rrgB is not expressed, as already reported by 
Falker et al. and Le Mieux et al. (25, 111), or in the presence of nonpolymerizing 
RrgB K183A. In this case, the mutated RrgB is competing with RrgA for the linkage to 
RrgC, as demonstrated by the presence of RrgB-RrgC hetero-oligomers. 
Concomitant detection of RrgA-RrgC hetero-oligomers even under these conditions 
further strengthens the idea that in wild-type bacteria, although not detectable by 
electron microscopy analysis of purified pili, a fraction of RrgA and RrgC might be 
directly linked to each other. 
 In conclusion, this study provides additional information elucidating pilus 
proteins features and also paves the way to the rational design of new RrgB-based 
molecules to implement a protein-based vaccine against pneumococcal disease. 
Moreover, the newly acquired structural and dynamic information on the RrgB 
molecule provided by this study suggests that the conformational flexibility of D1 is 
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pivotal for the protein-antibody recognition process. These findings together with the 
new functional information could be used to better understand pilus functions and its 
role in pathogenesis. 
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CHAPTER 4 
Investigation on the interaction between factor H 
binding protein and factor H 
 
Paper in preparation 
 
4.1. Introduction 
The ability to evade the surveillance of the immune system is a key 
determinant for the survival of pathogens within their hosts. In particular, the 
complement cascade provides the first line of defence against external pathogenic 
agents, and it is therefore quite expected that co-evolution of humans and 
microorganisms resulted in a variety of microbial molecules able to protect the 
microbe from the complement attack. Different molecular mechanisms have been set 
up by bacterial pathogens to escape human complement, including recruitment of 
complement inhibitors on the surface and degradation or inactivation of key effectors 
(112). Bacterial molecules able to sequester complement inhibitors on bacterial 
surfaces are in principle good targets of vaccine-induced antibodies and may be 
used to design vaccines focused on the generation of complement dependent 
bactericidal and opsonopahgocytic antibodies activities (113).  
The factor H binding protein (fHbp) of Neisseria meningitidis is a 27kDa 
membrane-anchored lipoprotein (10, 15) and represents an example of protein able 
to contribute to the bacterial survival by binding a negative regulator of the 
complement cascade. It can binds human factor H (hfH) (18). The bacterium is able 
to cover its surface with factor H allowing mimicking a human tissue and avoiding 
complement-mediated lysis. Factor H is a single polypeptide chain plasma 
glycoprotein (155 kDa), composed of 20 units of 60 amino acids (114), named short 
consensus repeats (SCR) or complement control protein modules (CCP). The 3D 
structure of several SCRs have been determined, showing a globular structure with 
six-stranded antiparallel β-sheets connected with loops and turns. fH plays a central 
role in inhibiting the alternative complement pathway by contrasting the assembly of 
an active C3 convertase (115-117).  
Recently, important advances have been done on the knowledge of structural 
basis of the interaction between fHbp and human factor H. The crystal structure of 
the complex formed by fHbp and the sixth and seventh domains of human factor H 
(CCP6-7) solved by Schneider et al. (118) evidenced that the factor H binds fHbp at 
the same site devoted to recognition of host glucosamino-glycans (GAGs). On the 
other side, fHbp contacts factor H with the groove formed between its N- and C-
domains (figure 1).  
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The centre of the interaction site is occupied by two residues, namely E218 
and E239, which have been proposed to mimic the poly-anionic structure of GAGs 
that normally drives the interaction of fH with human cell surfaces (119). 
In the present study we characterized the interaction of fHbp with fH in 
aqueous solution by nuclear magnetic resonance (NMR). Chemical shift perturbation 
analysis  performed in presence of recombinant CCP6-7 and CCP5-7 domains 
evidenced that in both cases the fHbp binding sites to fH were virtually identical and 
largely overlapping to that already identified by X-ray crystallography in CCP6-7, 
excluding that CCP5 could interact  in a direct and stable way with a specific portion 
of the fHbp surface. Prompted by signal perturbations observed on amino acids 
located at periphery of fH binding site, it will be possible to design in the future a 
panel of fHbp in order to explore the influence of such residues on the fHbp-fH 
interaction. This approach will allow us to identify additional amino acids contributing 
to the fHbp ability to bind fH, providing evidences that other mechanisms in addition 
to molecular mimicry can contribute to the fHbp affinity for fH. 
 
4.2. MATERIALS AND METHODS  
NMR sample production and NMR measurements - Recombinant fHbp (residues 
Met-7–Gln-255) was expressed in Escherichia coli as already described. The 
interaction of CCP5-6 and CCP5-7 with 15N-labeled fHbp was investigated by NMR 
spectroscopy with 1H–15N TROSY-HSQC experiments. All the NMR experiments 
were performed at 298 K on a Bruker Advance 900 spectrometer, working at 900.13 
MHz frequency and equipped with a cryogenically cooled probe. Titrations with the fH 
constructs were performed on 0.2 mM 15N-labelled fHbp protein samples with the 
unlabelled CCP5-6 or CCP5-7 up to an fHbp CCP molar ratio of 1:1. 1H and 15N 
resonances assignment for the fHbp protein was already available (17). All the 
samples used were in 20 mM PBS (90% H2O and 10% D2O) at pH 7.0. Solvent 
accessibility for fHbp residues was calculated with the program NACCESS (120); 
only residues with a GLOBAL solvent accessibility larger than 40% were considered 
for the mapping. 
Figure 1. Crystal structure of the complex fHbp (blue) 
and CCP67 (res). PDB ID 2W80 
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4.3. Results and discussion 
NMR mapping of the fH-fHbp interaction -The interaction between fHbp and the 
recombinant CCP5-7 was investigated through NMR spectroscopy, by analyzing the 
perturbations caused in the 1H–15N TROSY-HSQC spectra of 15N-labeled fHbp upon 
addition of unlabelled CCP5-7 up to a fHbp:CCP5-7 ratio of 1:1. Chemical shift 
variation of NH cross peaks observed in the 1H–15N TROSY-HSQC spectra upon 
addition of CCP5-7 indicated that the two proteins are interacting. The fHbp-CCP5-7 
complex exchanged with the free proteins at rates slower than the resonance 
frequency differences between the two forms (i.e., in the range of milliseconds). 
Residues of fHbp experiencing different chemical shift upon addition of CCP5-7, are 
shown in Figure 2 and listed in Table 1. They comprise an extensive region which 
involves both the N- and C-terminal domains of fHbp, largely overlapping to the fH 
binding site described in the crystal structure of the fHBP-CCP6-7 complex (118). 
The total number of perturbed, surface-exposed residues in solution define a larger 
contact area compared to that found in the crystal, but still contains all the residues 
located at the interface between fHbp and CCP6-7, suggesting that also in solution 
and in the presence of a longer construct of fH, the fHbp interaction with domains 6 
and 7 is essentially maintained. Moreover, additional residues, distinct from those 
forming the CCP6-7 binding site, were perturbed by the addition of CCP5-7. A first 
group consisted of solvent-accessible amino acids (Figure2A) located in the linker 
connecting the N- and C-domains of fHbp (Thr139, Phe141, Asp142 and Lys143) 
and several buried residues located at the domain-domain interface of fHbp (Gln97, 
Tyr99, Gln101, His103, Phe129, Gly132, Ala135, Ile226, Gly236, Ser237, His248, 
Ile249, Gly250 and Leu251, Figure2B). Their sensitivity to the presence of CCP5-7 
suggested that a molecular rearrangement could occur in fHbp during the formation 
of the fHbp-CCP5-7 complex. A second region was formed by residues whose 
localization on the protein surface was theoretically compatible with contacts to 
CCP5. To test this hypothesis we performed the same NMR measurements in 
presence of CCP6-7. However the pattern of perturbed residues remained essentially 
unchanged, ruling out the possibility that CCP5 engage specific and stable contacts 
with the fHbp surface and suggesting that the interaction of fHbp with fH was limited 
to domains 6 and 7. Our NMR data are in line with previous epitope mapping studies 
on fHbp. Beernink and colleagues have shown that Gly121 and Lys122, two residues 
solvent-exposed located in the loop between strands 7 and 8 of the N-terminal 
domain of the molecule, are recognized by monoclonal antibodies as JAR3 and 
JAR5 (121) that inhibit fH binding. Accordingly, spectral perturbations were observed 
for their NH cross peaks upon addition of CCP5-7 and CCP67 to fHbp. On the other 
side, we demonstrated by FACS experiments that the fHbp interaction with fH could 
not be prevented by the monoclonal antibody MAb502 binding to fHbp (122). 
Residues involved in the interaction with MAb502 are Arg204, Glu146-Arg149, 
Ala174, Lys230 and Glu233. As expected, the latter residues are indeed not affected 
by CCP5-7 and CCP67 binding confirming that there is not overlapping between fH 
and MAb502 binding sites. Based on the NMR data it will be possible to investigate 
by mutagenesis of single residues about the role of additional residues in the 
interaction between fH and fHbp. 
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RESIDUES  
 
 
BURIED 
Leu31,Gln32,Leu36,Ser39,Val40,Glu44,Tyr57,Asn64,Ser74,Phe76,Phe78, 
Arg80,Gln81,Ile82,Ile89,Ser93,Phe96,Gln97,Val98,Tyr99,Gln101,His103, 
Thr107,Phe109,Gln110,Thr111,Ile114,Asp116,Phe129,Gly132,Ala135,Tyr152, 
Lys165Gly177,Gly179,Ala196,Ile198,Ala206,Val207,Gly210,Val212,Gly220, 
Leu224,Gly225,Ile226,Gly236,Ser237,Ala238,Thr242,His248,Ile249,Gly250, 
Leu251 
 
EXPOSED 
Asp37,Gln38,Arg41,Lys42,Asn43,Lys45,Thr56,Glu83,Gly86,Leu91,Glu95, 
Glu112,His119,Gly121,Lys122,Val124,Lys126,Arg127,Gln128,Arg130,Thr139,
Ser140,Phe141,Asp142,Lys143,Asp160,Gly163,Glu188,Lys199,Ser211, 
Leu213,Lys219,Ser221,Ser223,Lys241 
Table 1 
 
Figure 2. A) Residues experiencing chemical shift differences mapped on the molecular surface of the free fHbp. Surface-
exposed and buried residues, whose amide NMR signals were perturbated (> 0.1 ppm) upon addition of hfH567, are shown in 
magenta and red, respectively. Residues whose amide signals were not perturbated upon addition of hfH567, prolines, and 
residues that could not be accurately analyzed due to spectral overlap, are in gray. B) Residues mapped on the molecular 
surface of the free fHbp (PDBID 2KC0) and located at the interface of the fHbp-hfH67 complex in the crystal structure are 
shown in magenta 
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CHAPTER 5 
Neisseria meningitidis fHbp interacts with 
xenosiderophores in vitro 
 
Paper in preparation 
 
5.1. Introduction 
Neisseria meningitidis, a Gram-negative bacterium that colonizes the upper 
respiratory tract of 10% of healthy human population, is adapted to grow only in 
humans. With a frequency of 1 in 100,000 populations, the bacterium invades the 
bloodstream and becomes a severe pathogen, causing sepsis and meningitis. 
Vaccination with capsular polysaccharides induces serogroup specific protective 
antibodies. Meningococcal capsular polysaccharide vaccines are available 
against serogroups A, C, Y, and W135 (123-125). On the contrary, the 
development of a vaccine against serogroup B, still responsible for a significant 
percentage of invasive diseases, has been protracted due to the immunologic 
cross-reactivity of B polysaccharide with human tissues. Recently, new 
perspectives to meningococcal B (menB) prevention have been opened by the 
identification of suitable protein-based vaccine antigens identified by mining the 
bacterial genome (12). One of the most promising antigens is the factor H-binding 
protein (fHbp), whose solution structure was recently determined by NMR 
spectroscopy (17). This is a 27kDa membrane-anchored lipoprotein (10, 15) 
present on the surface of all strains of N. meningitidis and elicits protective 
bactericidal antibodies. fHbp binds human factor H (hfH), a negative regulator of 
the alternative complement activation (18). The bacterium is able to cover its 
surface with factor H allowing mimicking a human tissue and avoiding 
complement-mediated lysis. However, little else was known about the in vivo 
functions of this protein prior to vaccine development. NMR analysis of the C-
terminal structure of fHbp (17) revealed similarities to lipocalins, a diverse group 
of proteins found in plants, fungi, bacteria, vertebrates and invertebrates that 
participate in many biological functions including binding to molecules devoted to 
iron recruitment from the environment collectively called siderophores (126). 
Siderophores (from the Greek: ―iron carriers‖) are defined as relatively low 
molecular weight, ferric ion specific chelating agents elaborated by bacteria and 
fungi growing under low iron stress Even when bacteria colonize multicellular 
organisms, whether they are saprophytic or pathogenic microbes, they do not find 
freely available iron, the role of the siderophores is to scavenge iron from the 
environment and to make the mineral, which is almost always essential, available 
to the microbial cell (127) (Figure 1). Siderophores are frequent targets of the 
innate defense system (128) and many bacteria evolved the ability to use 
siderophores produced by other microorganisms (xenosiderophores) (129, 130). 
Although no siderophores produced by N.meningitidis have been identified so far, 
a meningococcal surface protein, FetA, is a known receptor for enterobactin 
(131), a siderophore produced by many enteric bacteria.   
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Prompted by its structural similarity to lipocalins, we investigated on the possible 
activity of fHbp as siderophore binding protein. In particular, we analyzed the ability 
by the protein to bind prototypic siderophores such as enterobactin, salmochelin and 
yersiniabactin. Our data revealed affinity for enterobactin and the binding site has 
been mapped on the protein surface by NMR spectroscopy. 
This study provides the first evidences that, additionally to bind factor H, this protein 
can be involved also in additional mechanisms for the survival in the host. 
 
 
 
 
 
Figure 1.A) Schematic representation of iron uptake mediated by siderophores in Gram-negative bacteria. The pathway 
requires an outer membrane receptor, a PBP, and an inner-membrane ABC transporter. Transport through the outer membrane 
receptor requires the action of the TonB system (TonB, ExbB, ExbD). B) Two different class of siderophores. 
 
5.2. Materials and methods 
rfHbp-His Expression and purification- The fhbp gene was amplified by PCR on 
the chromosomal DNA of N. meningitidis strain MC58 and cloned into pET21b+ 
vector (Novagen) under the control of the T7 promoter. fHbp was expressed in the 
Escherichia coli BL21 (DE3) strain as a C-terminal histidine fusion. Protein 
expression was induced by Isopropyl1-thio-β-D-galactopyranoside (IPTG), (Sigma), 
then rfhbp was purified through a nickel chelating affinity chromatography using a 
HisTrap HP column (GE Healthcare) followed by cationic exchange chromatography. 
The purified protein was dialyzed in PBS buffer. For NMR analysis, the clone BL21 
(DE3) E.coli was grown in ISOGROTM 15N (Sigma). After protein purification, the final 
A B 
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product was dialyzed in 20 mM sodium phosphate, pH 7.2, a specific requirement for 
NMR.  
fhbp enterobactin interaction - Native Page Gel-100 micrograms of purified full-
length rfHBP-his or rpK1 0405B fragment from ExpEc (control), were mixed and 
incubated for 1h or 24 h with 3, 6 or 9  μg of ferric enterobactin (EMC). Samples were 
mixed with Tris-glycine native sample buffer and loaded on Novex Tris-glycine or 
Novex Tris-acetate native gels (Invitrogen). Gels were run at 80 V constantly for 2.0 h 
and stained with SimplyBlue Safe Stain (Invitrogen).  
fHbp enterobactin interaction studies by NMR spectroscopy-The interaction of 
ferric–enterobactin (FeIII(Ent)3-), -salmochelin (FeIIISalm)3-) and -Yersiniabactin 
(FeIII(Yers)3-) with 15N-labeled fHbp was investigated by NMR spectroscopy 
performed at 298 K on a Bruker Avance 900 and 800 spectrometers, at proton 
nominal frequencies of 899.20 and 800.13 MHz, respectively, using triple-resonance 
(TXI 5-mm) probes equipped with pulsed-field gradients along the z-axis. The 
interaction between fHbp and enterobactin iron free was also investigated. Titrations 
were performed on 0.5 mM 15N-labeled fHbp protein samples with enterobactin up to 
a fHbp–enterobactin molar ratio of 1:1.5. 1H and 15N resonance assignments for the 
fHbp protein were available (17). All samples were in 20 mM phosphate buffer (90% 
H2O and 10% D2O) at pH 7.2. All 2D spectra were processed using TOPSPIN 
software. 
Docking calculations between fHbp and FeIII(Ent)3- were performed with 
HADDOCK2.0 (132, 133). Twenty conformers of the fHbp solution structure (PDB ID 
2KC0) and the PDB coordinates of the small molecule extracted from the crystal 
structure on the human siderocalin NGAL complexed with FeIII(Ent)3- (PDBID 3CMP) 
were used as input. The topologies and parameter files for FeIII(Ent)3-, which are 
necessary to run HADDOCK2.0, were generated by PRODRG 
(http://davapc1.bioch.dundee.ac.uk/prodrg/) (134) using the PDB coordinates 
extracted from the 3CMP crystal structure.  
The docking calculations in HADDOCK were driven by 9 active and 9 passive 
residues (Table 1), defined following the HADDOCK protocol (132, 133). Solvent 
accessibility of fHbp was calculated with NACCESS (120). Flexible regions of the 
proteins were defined based on the active and passive residues plus two preceding 
and following residues. In the initial rigid-body docking calculation phase, 1000 
structures of the complex were generated; the best 100 in terms of total 
intermolecular energy were further submitted to semiflexible simulated annealing and 
final refinement in water. The initial temperature for the second Torsion Angle 
Dynamic (TAD) cooling step with flexible side-chain at the interface was set up to 500 
K. The number of MD steps for rigid body high temperature TAD and during the first 
rigid body cooling stage were set up to zero while the number of MD steps during the 
second and the third cooling stages with flexible side-chains at interface were set up 
to 500. The final 100 structures were then clustered using a cutoff of 2.0 Å of RMSD 
among any structure of a cluster. Clusters containing at least 5 structures were 
analyzed. 
Active residues Gly148, Arg149, Ala150, Thr151, Arg153, Lys230, Gln232, Lys254, 
Gln255 
Passive residues Asp71, His103, Thr139, Gly147, Thr167, Thr169, Ala173, Gly229, 
Gln232 
Table 1 
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5.3. Results 
fHbp-siderophores interaction - Native Page Gel-The ability of recombinant fHbp 
to bind native enterobactin was initially investigated by native PAGE. Incubation with 
and without ferric enterobactin resulted in different patterns of migration. 
NMR mapping of fHbp-siderophores interaction-To address the molecular 
aspects of the interaction between FeIII(Ent)3- and fHbp, the perturbations caused in 
the 1H–15N- HSQC spectrum upon addition of Enterobactin iron free, FeIII(Ent)3-, 
FeIII(Salm)3- and FeIII(Yers)3- were analyzed and the fHbp residues involved in the 
protein-small molecule interaction were mapped onto the NMR structure (PDB ID 
2KC0). Addition of increasing amount of paramagnetic FeIII(Ent)3- to 15N-labeled 
fHbp resulted in progressive increase of the line-widths of some NH cross-peaks in 
the 1H–15NHSQC spectra (table 1), which disappeared at the 1:1.5. The protein 
residues involved in the protein-small molecule interaction were mapped onto the 
NMR structure (figure 2). 
Figure 2. Solution structure of fHbp (PDB ID 2KC0) with the mapping of residues engaged in the interaction with 
FeIII(Ent)
3-
. 
All residues, whose NH cross peaks disappear upon addition of FeIII(Ent)3-, were 
located on the C-terminal domain with exception of Ser102. No interaction was 
observed between protein and enterobactin iron free, salmochelin and yersiniabactin. 
Enterobactin iron free is less negatively charged at pH 7.2 than FeIII(Ent)3- and this 
could be one of the reason why we did not observed any interaction. We also added 
a solution of FeCl3 to the protein/apo-enterobactin 1:1.5 mixture, and the same 
signals broaden beyond detection indicating that both Coulombic attraction and 
cation-p interaction of the cathecole moiety could be important for binding. The 
importance of the presence of cathecole moieties is confirmed by the absence of 
interaction of fHbp with the hydromaxate siderophores yersiniabactin. Any changes 
were indeed observed in the the 1H–15N HSQC fHbp spectrum upon addition of 
yersiniabactin up to a 1:5 protein:small molecule ratio (Figure 3). Finally, the best 
model of the molecular docking shows the orientation of the FeIII(Ent)3- with respect 
to fHbp (figure 4). 
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Figure 3. A) Titration of fHbp with FeIII(Ent)
3-
. Superposition of the spectra on the protein alone (red) and the spectra at the end 
of titration with a molar ratio fHbp:FeIII(Ent)
3- 
1:2. B) Titration of fHbp with FeIII(Yers)
3-
. Superposition of the spectra on the 
protein alone (red) and the spectra at the end of titration with a molar ratio fHbp:FeIII(Yers)
3- 
1:5. 
 
Figure 4. Complex between fHbp and FeIII(Ent)
3- 
obtained with HADDOCK2.0. A) Superposition of the best ten complex 
structure obtained by HADDOCK2.0. B) Focalizing on one complex structure. 
 
Discussion 
fHbp, a subcapsular membrane bound protein, has gained importance as a 
meningococcal surface antigen because it is a component of several different 
protein-based candidate vaccines against meningococcal serogroup B strains (135, 
136). The ability to bind human factor H (hfH) without affecting its function, allows 
fHbp to play a crucial role in the evasion of the host defence mediated by the 
alternative complement pathway. NMR and X-ray resolution of the three-dimensional 
structure of meningococcal fHbp revealed a lipocalin-like fold in the Carboxyl-terminal 
domain, which might suggest a role in iron uptake. We found that fHbp interacts with 
enterobactin, a xenosiderophore produced by E.coli, in vitro. Our data identified the 
region interacting with enterobactin not in overlap with the fH contact area. This 
finding, which was confirmed by multiple experiments, strongly suggests that fHbp 
plays an important role in iron acquisition for the meningococcus and in the survival 
of the microorganism in the host during pathogenesis.  
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Streptococcus pneumoniae expresses on its surface adhesive
pili, involved in bacterial attachment to epithelial cells and vir-
ulence. The pneumococcal pilus is composed of three proteins,
RrgA,RrgB, andRrgC, each stabilized by intramolecular isopep-
tide bonds and covalently polymerized by means of intermolec-
ular isopeptide bonds to form an extended fiber. RrgB is the
pilus scaffold subunit and is protective in vivo in mouse models
of sepsis and pneumonia, thus representing a potential vaccine
candidate.The crystal structure of amajorRrgBC-terminal por-
tion featured an organization into three independently folded
protein domains (D2–D4), whereas the N-terminal D1 domain
(D1) remained unsolved. We have tested the four single recom-
binant RrgB domains in active and passive immunization stud-
ies and show that D1 is the most effective, providing a level of
protection comparable with that of the full-length protein. To
elucidate the structural features of D1, we solved the solution
structure of the recombinant domain by NMR spectroscopy. The
spectra analysis revealed that D1 has many flexible regions, does
not contain any intramolecular isopeptide bond, and shares with
theotherdomains an Ig-like fold. In addition,wedemonstrated, by
site-directedmutagenesisandcomplementation inS.pneumoniae,
that the D1 domain contains the Lys residue (Lys-183) involved in
the formation of the intermolecular isopeptide bonds and pilus
polymerization. Finally, we present a model of the RrgB protein
architecture alongwith themapping of two surface-exposed linear
epitopes recognized by protective antisera.
Streptococcus pneumoniae is an important human pathogen
responsible for diseases such as otitismedia, pneumonia, sepsis,
and meningitis (1–6). However, S. pneumoniae is also a com-
mon inhabitant of the respiratory tract of children and healthy
adults. This carriage state could represent a risk factor for the
development of respiratory diseases but also the source for
pneumococcal transmission to other individuals (7–9). Like
most streptococci, S. pneumoniae decorates its surface with
long filaments known as pili (10–14). Pneumococcal pili have
previously been associated with virulence and the capability of
the microorganism to adhere better to epithelial cells and to
colonize the nasopharynx (10, 15, 16). The pneumococcal pilus
is a multimeric structure consisting of three proteins (RrgA,
RrgB, and RrgC) polymerized by three sortase enzymes (SrtC1,
SrtC2, and SrtC3) through the formation of covalent intermo-
lecular isopeptide bonds (17–21). In particular, multiple copies
of RrgB are polymerized to form the scaffold of the pilus,
whereas the major adhesin, RrgA, and the putative anchor,
RrgC, are localized at the tip and at the base of the pilus, respec-
tively (15, 22, 23).
Recently, the structure of a major portion of RrgB (residues
184–627) was solved at a 1.6 Å resolution (24) and revealed an
organization into three independently folded IgG-like domains
(D2, D3, and D4, residues 184–326, 326–446, and 446–627,
respectively). On the contrary, the structure of the RrgB N-ter-
minal region (D1, residues 1–184), likely constituting a fourth
independently folded domain, remained unsolved due to the
failure to obtain the crystals of the full-length (FL)3 RrgB (24).
Interestingly, each of the D2, D3, and D4 domains is stabilized
by one intramolecular isopeptide bond. These covalent link-
ages, formed between Lys and Asn residues, have been found in
other pilus proteins (19, 25–28) and are thought to play a role
similar to that of disulfide bonds; they confer in fact a rigid
molecular architecture to the pili and make them less suscepti-
ble to proteolytic cleavage (Fig. 1).
In the pilus backbone assembly RrgB molecules are linked
together by sortases through intermolecular isopeptide bond
formation between a Thr within the C-terminal LPXTG motif
of a molecule and a Lys located at the N terminus of the follow-
ing molecule (18, 26, 29) (Fig. 1). In Corynebacterium diphthe-
riae, where the general principles of pilus assembly were first
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established, the functional Lys is located within a conserved
YPKN “pilin” motif (18, 27, 30). Nevertheless, this sequence
is not absolutely required for polymerization as demon-
strated by studies on the Spy0128 pilin of Streptococcus pyo-
genes, where the lysine forming the intermolecular isopep-
tide bond and responsible for pilus polymerization is located
into 159GSKVPI164 motif even though the YPKN pilin motif
is also present (26, 31).
RrgB, alongwith the other two pilus proteins RrgA andRrgC,
was previously shown to confer protection in mouse models of
infection and therefore is regarded as a potential candidate for a
new generation of protein-based vaccines (32, 33). We have
investigated the protective ability of the single recombinantD1,
D2, D3, and D4 domains of RrgB in a mouse model of sepsis,
and here we provide evidence that D1 is the most protective,
followed byD4. Furthermore, we present the solution structure
of the recombinant D1 obtained by NMR spectroscopy and
show that Lys-183 of D1 is engaged in the intermolecular iso-
peptide bond formation during pilus polymerization. Finally,
we propose a possible model of the entire RrgB molecule and
show the positions of two linear epitopes possibly involved in
the protection mechanism.
MATERIALS AND METHODS
Bacterial Strains and Cultures—For the animal experiments,
the S. pneumoniaeTIGR4 (serotype 4) strain was used. Bacteria
were grown, frozen in aliquots at80 °C, and titrated as already
reported (32). Immediately prior to challenge, frozen aliquots
were thawed and diluted in PBS to reach the working
concentration.
Cloning and Protein Expression and Purification—Standard
recombinant DNA techniques were used to construct the
expression plasmids (pET21b; Novagen) and to express and
purify the recombinant C-terminal His-tagged proteins (for
details, see supplementalMaterials andMethods, and the prim-
ers used are listed in supplemental Table S1). The affinity-pu-
rified proteins were subsequently used to immunize CD1 mice
or rabbits for antibody generation (Charles River Laboratory)
and BALB/c mice to evaluate the protective efficacy.
Complementation Plasmids—Wild-type or mutant rrgB
genes were amplified from chromosomal DNA of TIGR4 strain
by PCR by using the primers listed in supplemental Table S2;
point mutations were introduced by overlap extension PCR by
using specific primers (supplemental Table S2). PCR products
were then cloned into the complementation plasmid pMU1328
between the BamHI and SalI restriction sites (34). Expression of
RrgB or RrgB mutated forms was under control of the erythro-
mycin constitutive promoter (Pc) which was amplified with the
primers listed in supplemental Table S2 and cloned immedi-
ately upstream rrgB (EcoRI, BamHI). All plasmids were con-
firmed by sequencing.
Generation of rrgB Deletion Mutants and rrgB Comple-
mentants—A TIGR4 rrgB isogenic mutant was generated by
allelic exchange. Fragments of 500 bp upstream and down-
stream the target genewere amplified by PCR (oligonucleotides
are listed in supplemental Table S2) and spliced into a kanamy-
cin resistance cassette by using overlap extension PCR; the PCR
fragments were then cloned into pGEMt (Promega) and trans-
formed in S. pneumoniae with conventional methods (35). To
select the bacteria in which the target gene was replaced with
the resistance cassette, bacteria were plated on blood-agar
plates with kanamycin (500 g/ml). The presence of the iso-
genic mutation was confirmed by PCR andWestern blot (WB)
analysis. To obtain RrgB-complemented mutants, pMU1328
plasmids containing WT rrgB or rrgB mutated forms were
transformed into TIGR4 rrgB with conventional methods.
Transformants selection was performed by supplementing
media with kanamycin (500 g/ml) and erythromycin (1
g/ml). The complemented mutants were then analyzed by
PCR; expression of FLWT RrgB or RrgBmutants was detected
by WB analysis of whole cell lysates.
SDS-PAGE and Western Blot Analysis—SDS-PAGE analysis
was performed using NuPAGETM 4–12% BisTris gradient gels
(Invitrogen) according to the manufacturer’s instructions.
Hi-MarkTM prestained HMW (Invitrogen) served as protein
standard. Gels were processed for WB analysis by using stan-
dard protocols. Mouse polyclonal antibodies raised against
recombinant His-tagged RrgB were used at 1/3000 dilution.
Secondary goat anti-mouse IgG alkaline phosphatase-conju-
gated antibodies (Promega) were used at 1/5000, and signals
were developed by usingWestern Blue Stabilized Substrate for
Alkaline Phosphatase (Promega).
Animal Experiments—Animal studies were done in compli-
ance with the current law approved by the local Animal Ethics
Committee and authorized by the Italian Ministry of Health.
Female, 6-week-old, specific pathogen-free BALB/c mice
(Charles River) received three intraperitoneal immunizations, 2
weeks apart. Each dose was composed of 20 g of either the
single RrgB domains or the FL RrgB, or of a combination of the
four RrgB domains (D1D2D3D4), 10 g each, along with
400g of aluminumhydroxide as an adjuvant, in a final volume
of 200 l of PBS. Control animals received the same course of
saline plus adjuvant. Ten days after the third immunization,
samples of sera were obtained from each animal and pooled
according to the immunization group to be used in passive
serum transfer experiment. Two weeks after the third immuni-
zation, each mouse was challenged intraperitoneally with a
mean dose of 1.6 102 cfu of TIGR4. Bacteremia was evaluated
24 h after challenge, andmortality coursemonitored for 10 days
after challenge as already reported (32). The animals were
euthanized when they exhibited defined humane end points
that had been preestablished for the study in agreement with
Novartis Animal Welfare Policies.
FIGURE 1. Schematic representation of pilus backbone protein RrgB. Pilus
scaffold is composed by multiples copies of RrgB protein in a head-to-tail
arrangement. Pilus polymerization occurs through intermolecular isopeptide
bonds (red), whereas each RrgB protein is stabilized by intramolecular isopep-
tide bonds (black). Lys-183 as a residue involved in the intermolecular bond
has been identified in the present work.
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For passive protection experiments, 8-week-old mice were
used. Fifteen minutes before TIGR4 intraperitoneal challenge
(102 cfu/mouse), eachmouse received intraperitoneally 50l of
pooledmouse sera against recombinant D1 or D4, or of control
sera obtained immunizing with adjuvant plus saline.
Statistical Analysis—Bacteremia and mortality course were
analyzed by theMann-WhitneyU test. Survival rates were ana-
lyzed by Fisher’s exact test. One-tailed or two-tailed tests were
used to compare immunized groups with the control group or
each other, respectively. Values of p  0.05 were considered
and referred to as significant. Values of p  0.1 were referred to
as a trend.
Flow Cytometry on Entire Bacteria—TIGR4 were grown in
Todd-Hewitt yeast extract broth to an exponential phase
(A600  0.25), fixed with 2% formaldehyde, and then stained
with pooled mouse antisera raised against FL RrgB or RrgB
domains at 1:400 dilution. Mouse IgG were detected with
FITC-conjugated goat anti-mouse IgG (Jackson Laboratories)
at 1:100 dilution, and bacterial staining was analyzed by using a
FACS-Calibur cytometer (Becton Dickinson). Sera from mice
immunized with PBS plus adjuvant were used as negative
control.
ELISA—96-wellMaxiSorpTM flat-bottomplates (Nunc)were
coated with 0.2 g/well FL RrgB overnight at 4 °C. Plates were
then washed three times with PBS/0.05% Tween 20 and satu-
rated for 1 h at 37 °C with PBS/1% BSA. Following three wash-
ing steps with PBS/0,05% Tween 20, the plates were incubated
for 2 h at 37 °C with serial dilutions of the pooled mouse sera.
After another three washing steps, bound antigen-specific
mouse IgGs were revealed with alkaline phosphatase-conju-
gated goat anti-mouse IgG (Sigma), followed by the phospha-
tase alkaline substrate p-nitrophenyl phosphate (Sigma). The
intensity of color was quantified with an ELISA plate reader at
A405. The antibody titer was expressed as the log10 of the recip-
rocal of the serum dilution that gave A405  1.
PepScan Analysis—Arrayed peptides were synthesized in
situ on glass fiber membranes. Membranes were conditioned
by wetting with ethanol and washing three times for 5 min in
TTBS (50 mM Tris-HCl, pH 7.0, 137 mM NaCl, 2.7 mM KCl,
0.05% Tween 20). After overnight blocking at 4 °C in MBS (2%
drymilk inTTBS),membraneswere incubated for 1.5 h at 37 °C
with polyclonal antisera (1:3000 inMBS) followed by secondary
goat anti-mouse IgG alkaline phosphatase-conjugated antibod-
ies (1:5000 in MBS; Promega), and signals were developed by
usingWestern Blue Stabilized Substrate for Alkaline Phospha-
tase. For image processing, membranes were scanned using an
Epson V750 Pro scanner at 800 dpi, 48-bit color depth andwith
gamma 1.0 full linear response.
NMRCharacterization of RrgB D1 Domain—Expression and
purification of labeled D1 were carried out as described in the
supplemental Materials and Methods. NMR spectra were
acquired at 298 K on Avance 900, 800, 700, and 500 MHz
Bruker spectrometers, all equipped with a triple resonance
cryoprobe. The NMR experiments, used for the backbone and
the aliphatic side chain resonances assignment recorded on
13C/15Nand 15Nenriched samples or on unlabeledD1 samples,
are summarized in supplemental Table S3. Backbone dihedral
angle constraints were derived from 15N, 13C’, 13C, 13C, and
Ha chemical shifts, using TALOS (36). Distance constraints
for structure determinationwere obtained from 15N-edited and
13C-edited three-dimensional NOESY-HSQC. 3131 meaning-
ful proton-proton distance restraints (supplemental Table S4),
with 114  and 120  backbone dihedral angles restraints were
included in structure calculations. The exchangeability of the
backbone amide hydrogen nuclei with solvent protons was
investigated through a 1H-15N HSQC experiment performed
on a protein sample dialyzed against deuterated buffer for 3
days. Hydrogen bond constraints for the slowly deuterium-ex-
changing amide protons of the -strands were introduced at
later steps of the structure calculations.
Structure calculations were performed through iterative
cycles of CYANA-2.1 (37) followed by restrained energy mini-
mization with the AMBER 10.0 Package in explicit water sol-
vent (38). The quality of the structures was evaluated by using
the iCING validation program (for details, see supplemental
Table S4). The program MOLMOL was subsequently used for
structure analysis (39).
The final bundle of 20 conformers ofD1has an average target
function of 1.36  0.13 (CYANA units). The average backbone
r.m.s.d. value (over residues 28–183) is 0.71  0.19Å, and the
all-heavy atoms r.m.s.d. value is 0.96  0.16. Per-residue
r.m.s.d. values are shown in supplemental Fig. S1.
Heteronuclear Relaxation Data—The dynamic properties of
D1 have been characterized experimentally through 15N relax-
ation measurements. 15N longitudinal and traverse relaxation
rates (40) and 15N{1H}NOEs (41) were recorded at 298 K at 500
MHz, using a protein concentration of 0.8 mM.
The average backbone 15N longitudinal R1 and transversal R2
relaxation rates and 15N{1H} NOE values are 1.45  0.1 s1,
16.18  1.5 s1, and 0.71  0.04, respectively (supplemental
Fig. S2). They are essentially homogeneous along the entire
polypeptide sequence, with the exception of residues located at
the C and N termini and three loop regions (56–69, 148–162,
and 173–177). The correlation time for the molecule tumbling
(c), as estimated from the R2/R1 ratio, is 11.49  1.9 ns, con-
sistent with themolecular mass of themonomeric protein. The
relaxation data were analyzed according to the model-free
approach of Lipari and Szabo (42, 43) using TENSOR2 (44)
(supplemental Fig. S2).
Rigid Body Fitting—Theprocedure used to accommodate the
NMR D1 structure into the EM map of the whole pilus previ-
ously generated (24) followed the same procedures used for the
fitting of the RrgBD2-D4 x-ray crystal structure and the D1
computer model into the EM pilus map (22). A preliminary
rigid body fitting of theD2–D4 crystal fragment was performed
by using CHIMERA (45–47) followed by a rigid body fitting of
the D1 NMR coordinates into the leftover N-terminal apical
volume of the pilus. The D1 NMR coordinates were first fitted
manually using CHIMERA by placing as much of the atomic
structure as possible into the EMdensitymap, approximately in
the position thought to be correct. This step was then followed
by a rigid-body fitting using the “fit model in map” tool from
CHIMERA. This tool calculates, for the selected atoms, a posi-
tion that maximizes locally the sum of the densities. The eval-
uation of the correlation coefficient values, the resulting aver-
agemap value at the fit atoms, the number of fits atoms outside
Protective RrgB D1 Domain Involved in Pilus Polymerization
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the lowest value contour surface displayed were the parameters
used to assess the fit of the D1 molecule.
RESULTS
Distinct Domains of RrgB Provide Protection in Active Immu-
nization Experiments—The protective efficacy of each of the
four RrgB domains or of a mixture of them was assessed in a
mouse model of intraperitoneal challenge (TIGR4) in two dis-
tinct experiments, performed under the same conditions,
which were combined to reach n  13–16 mice/group. The
results are summarized in Fig. 2,A andB, and detailed statistical
analysis is provided in supplemental Table S5A.
All RrgB domains except D3 afforded significant protection
against bacteremia (Fig. 2A), giving a reduction of the cfu geo-
metric mean by 1–2 logs with respect to the controls. These
values were similar to those afforded by the FL RrgB and by the
combination of the four domains D1D2D3D4. The
results of mortality are reported in Fig. 2B and supplemental
Table S5A. D1 and D4 conferred significant increase of
survival time, similar to FL RrgB and the combination
D1D2D3D4. In particular, themedian survival for the D1
groupwas 2.5 days higher respect to that of the control group (4
versus 1.5 days). At the end of the mortality observation, a sig-
nificant survival rate was found forD1 (44% survival), D4 (27%),
FL RrgB (44%), and D1D2D3D4 (31%) groups.
N-terminal D1 Domain Is the Most Protective in Vivo—
Among the single RrgB domains, D1 andD4 showed themost
significant protective efficacy and were therefore analyzed
further in a larger group of mice. Four different experiments,
carried out under the same conditions, were combined to
FIGURE 2. RrgB domains are protective in active immunization experiments. A and C, bacteremia. Circles represent the log cfu/ml of blood for individual
animals; horizontal bars represent the mean value of the log cfu/ml  S.E. for the group; the dotted line marks the detection limit (values under the dotted line
correspond to animals in which no cfu were detected). The treatment groups are indicated on the bottom. B and D, survival. The survival course for each group
is represented. The treatment groups are indicated close to each of the corresponding survival lines. A and B, n  13 for D2 group, 15 for D4 and control (alum
ctrl) groups, 16 for the remaining groups. C and D, n  31 for each of the groups. ***, p  0.001; **, p  0.01; *, p  0.05.
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reach n  31 animals/group. The results are shown in Fig. 2,
C and D, and detailed statistical analysis is provided in sup-
plemental Table S5B. In terms of bacteremia (Fig. 2C), both
D1 and D4 afforded highly significant protection, with a cfu
geometric mean by 2.6 and 1.5 logs lower, respectively, than
that of the control group, and 8 animals from the D1 group in
which cfu were undetectable. The reduction of bacteremia
was significantly superior in D1 than in the D4 group.
In terms of mortality course (Fig. 2D), both D1 and D4 con-
ferred significant protection. The increase of survival time
afforded by D1 showed a better trend than that of D4. In par-
ticular, only for the D1 group was the median survival time
higher than that of the control group (7.5 versus 1.5 days). At
the end of the mortality observation, the D1 group showed the
highest survival rate, i.e. 45% versus 21% observed for D4. An
evident difference of survival rates between D1 and D4 groups
was observed.
The possible relevance of antibodies in the protection elic-
ited by D1 and D4 was investigated by a passive serum transfer
experiment, with groups of 8mice. The results are shown in Fig.
3, and detailed statistical analysis is provided in supplemental
Table S5C. Both anti-D1 and anti-D4 sera elicited significant
protection against bacteremia (Fig. 3A), with cfu geometric
means lower by 2.6 and 1.6 logs, respectively, than that of the
control group. Only anti-D1 serum afforded significant protec-
tion against mortality, giving 100% survival rate, whereas
santi-D4 gave a protective trend, with 60% survival rate. These
results indicate that immunization with D1 domain and at a
lower extent D4 domain, elicits functional antibodies that may
play a role in the protection.
D1 and D4 Antisera Recognize the Native Pilus and Linear
Epitopes within RrgB—To investigate the differences in protec-
tive efficacy exerted by the isolated RrgB domains with respect
to the FL RrgB in the in vivo assays, mouse sera were tested
for their capability of recognizing the native pilus and the
recombinant FL RrgB. Sera were probed against entire TIGR4
bacteria by FACS analysis. Sera raised against D1, D4, and
D1D2D3D4 gave a fluorescence intensity comparable
with that obtainedwith anti-FL RrgB, whereasD2- andD3-spe-
cific antisera recognized the native pilus less effectively. To
explain the lower recognition efficacy observed with D2 and
D3, the same sera were titrated in ELISA against the recombi-
nant FLRrgB. As shown in supplemental Fig. S3, antibody titers
elicited by D2 and D3 immunization toward FL RrgB were
about 10 times lower than those obtained by immunization
with D1, D4, D1D2D3D4, and FL RrgB, consistent with
the results obtained by FACS analysis on the polymerized
native RrgB.
To gainmore insights on the epitopes recognized by the pro-
tective D1 and D4 polyclonal antibodies, a PepScan approach,
suitable for identifying linear epitopes, was applied. Overlap-
ping 15-mer peptides with an offset of 5 residues were synthe-
sized in situ on a glass fiber membrane. The library of peptides
tested covered residues 25–190 of D1 and 444–628 of D4.
Incubation with the anti-D1 serum (previously used in passive
protection experiments) revealed a single linear epitope cover-
ing residues 40–59 (D1-1) (Fig. 4B), whereas anti-D4 serum
detected a unique linear epitope (D4-1) spanning residues 494–
508 (Fig. 4C).
Solution Structure of theD1Domain—The solution structure
ofD1was investigated byNMRspectroscopy. Its 1H-15NHSQC
spectrum showed well dispersed resonances indicative of an
overall well folded protein (supplemental Fig. S4). D1 showed a
common IgG-like  sandwich fold (41 Å  48 Å  30 Å) and a
topology of secondary structure elements drawn in Fig. 5. The
core of the structure was formed by seven parallel and antiparallel
-strands: 1(36–39), 4(80–85), 7(119–121), 8(127–130),
9(138–143), 10(166–169), and 11(178–180). These -strands
were arranged in two sheets (comprising1,8,11 and4,7,9,
10, respectively) packed against each other and flanked by two
longsegments (40–78, 87–117) locatedbetweenstrands1and4
andstrands4 and7, respectively.An-helix (49–57), flankedby
two short -strands 2 (42–44) and 3 (73–75), was inserted
within the first segment.Twoadditional-strands5 (89–91) and
6 (97–101) formed a-hairpin structure inserted within the sec-
FIGURE 3. Anti-RrgB D1 and D4 sera are protective in passive serum trans-
fer experiments. Symbols are described in the Fig. 2 legend. n  8 for each of
the groups.
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ond segment. In 50% of 20 conformers of the D1 family an addi-
tional -sheet was formed by two short hydrogen-bonded
-strands (stretches 161–163 and 184–187).
The structure was well defined with the exception of three
long loops corresponding to the stretches 56–69, 148–162,
and 173–177 (supplemental Fig. S1). Heteronuclear relaxation
measurements revealed that residues in the first two loops had
heteronuclear NOE and longitudinal R1 values lower and
higher than average, respectively (supplemental Fig. S2). This
behaviorwas a consequence of local internalmotions occurring
on a faster time scale with respect to the overall reorientational
correlation time (r) of the molecule and accordingly, a corre-
lation time (e) for these fast motions can be fitted for the pre-
vious mentioned loops (supplemental Fig. S2). In addition,
conformational exchange processes, occurring on the millisec-
ond-microsecond scale, affected some residues located in the
region 155–164, as monitored by transverse R2 relaxation rates
higher than the average (supplemental Fig. S2). These data indi-
cated that these loops experience higher flexibility, showing
accordingly a low number of long ranges 1H-1HNOEs (supple-
mental Fig. S5). For a few residues, the assignment of the back-
bone resonances was also not achieved (Glu-143, His-145, Ser-
146, Ser-148, Thr-149, Tyr-150, Val-152, andGly-160), likely as
a consequence of an increased localmobility. The loop between
strands9 and10 (residues 148–162)was themost disordered,
with a r.m.s.d. value of about 2 Å (supplemental Fig. S1). Con-
formational exchange processes on the millisecond-microsec-
ond time scale are observed also for the loop between strands
10 and 11 comprising residues 174–178.
The protein core is characterized by hydrophobic interac-
tions between residues located on the first (strands 1, 8, 11)
and second (strands 4, 7, 9, 10) sheets. A salt bridge
between two complementarily charged side chains of residues
Lys-41 and Glu-143 was also present. The aliphatic side chains
of residues Met-48, Ile-52, Ala-53, and Leu-56, all located on
one side of the -helix, formed hydrophobic interactions with
FIGURE 4. Polyclonal antibodies raised against D1 and D4 recognize the native pilus and linear epitopes within RrgB efficiently. A, TIGR4 bacteria were
incubated with mouse primary antibodies directed against the specified recombinant proteins (1:400 dilution) followed by FITC-conjugated goat anti-mouse IgG
(1:100 dilution). Bacterial staining was analyzed by flow cytometry (FACS-Calibur). Mouse control sera (immunized with PBS plus alum) were used as negative control.
B and C, glass fiber membranes with arrayed peptides synthesized in situ covering residues 25–190 (D1) and 444–628 (D4) of RrgB were incubated with anti-D1 (A) or
anti-D4 (B) polyclonal mouse antibodies (1:3000) and then with goat anti-mouse IgG alkaline phosphatase-conjugated antibodies (1:5000). Linear epitopes corre-
sponding to peptide sequences recognized by the antibodies are reported. Underlining marks common residues present in adjacent peptides in the PepScan.
FIGURE 5. Solution structure of the D1 domain. A, ribbon diagram with the
secondary structure elements. -Strands are shown in cyan, the -helix in red.
B, topology diagram. The -helix is represented by a red cylinder, and the
-strands are cyan arrows.
Protective RrgB D1 Domain Involved in Pilus Polymerization
APRIL 22, 2011 • VOLUME 286 • NUMBER 16 JOURNAL OF BIOLOGICAL CHEMISTRY 14593
 at N
ovartis G
lobal, on M
ay 11, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
aliphatic residues of2 and3 strands; these interactions deter-
mined the position of the helix with respect to the rest of the
protein.
A search for related protein structures performed through
the DALI Server (48) retrieved the N-terminal domain of the
SpaA pilus backbone protein of C. diphtheriae (Protein Data
Bank (PDB) code 3HTL; r.m.s.d. 2.1 Å), the C-terminal CNA3
domain of themajor pilin protein of Bacillus cereus BcpA (PDB
code 3KPT; r.m.s.d. 2.4 Å), and the N1 domain of the Strepto-
coccus agalactiaeminor pilin GBS52 (PDB code 2PZ4; r.m.s.d.
3.4 Å). Like D1, none of these domains contained intramolecu-
lar isopeptide bonds.However, only the SpaAdomain is located
at the N terminus of pilus backbone protein as D1; their overlay
is presented in Fig. 6A.
In an attempt to determine the orientation ofD1with respect
to the D2–D4 RrgB portion, a rigid body fitting of all the
domains into the shape of the native pilus obtained from cryo-
electronmicroscopy (cryo-EM)was attempted (24). Initial rigid
body fitting of the D2–D4 crystal structure into the cryo-EM
density map of the native pilus left an apical unoccupied vol-
ume, likely due to the absence of D1. However, when the simul-
taneous fitting of the D1 and the D2–D4 domains was carried
out, some portions of D1 could not be accommodated into the
apical empty volume (supplemental Fig. S6 and supplemental
Table S6). To model the FL RrgB, we merged the D1 and
D2–D4 structures into a single molecule by overlapping resi-
dues 188–191, shared by the C terminus of D1 and the N ter-
minus of D2–D4. The relative orientation of D1 with respect to
the others domains was then varied to best fit into the cryo-EM
map (Fig. 6B). The finalmodel, which represents only one of the
possible orientations of D1 with respect to the rest of the pro-
tein, does not present steric clashes betweenD1 and theD2–D4
domains. The two linear epitopes, previously identified to be
locatedwithin theD1 andD4 domains by peptide hybridization
with specific protective polyclonal antibodies (Fig. 4), when
mapped onto the FLmodel of RrgB, confirmed their superficial
localization (Fig. 6B).
Lysine 183 of D1 Is Required for Intermolecular Isopeptide
Bond Formation and Pilus Polymerization—Pili of Gram-posi-
tive bacteria are polymerized by means of intermolecular iso-
peptide bonds occurring between the Thr of the C-terminal
LPXTG motif of a RrgB molecule and a Lys located at the N
terminus of the following molecule (18, 29, 30). To identify the
Lys implicated in the intermolecular isopeptide bond forma-
tion between two consecutive RrgB monomers, a TIGR4 RrgB
deletion mutant (no longer able to assemble a pilus on its sur-
face) was created. Subsequently, RrgB expression and pilus
polymerization were restored in TIGR4RrgB by transforming
the mutant with plasmids expressing either wild-type RrgB or
RrgB mutated in single Lys residues (Lys3 Ala substitutions).
Sequence analysis revealed that the D1 contains the canonical
181YPKN184 pilin motif, with Lys-183 nicely superimposing
onto the functional SpaA Lys-190, as shown in Fig. 6A.
Noteworthy, D1 also presents the sequence fragment
160GSKAVP165, similar to the motif containing the Lys residue
functional for the pilus assembly in S. pyogenes Spy0128 (31).
Lys-183 and Lys-162, along with two additional Lys residues
(Lys-138 and Lys-309), located on D1 and D3 domains, respec-
tively, were selected and mutated.
WB analysis performed on whole cell bacterial lysates using
rabbit polyclonal antisera raised against RrgA, RrgB, or RrgC
revealed that all of the pilus proteins were expressed in all of the
complemented mutants (Fig. 5). However, the typical pilus-as-
sociated high molecular weight ladder was revealed only in the
case of TIGR4RrgB complemented with RrgB wild type or
RrgB mutated in Lys-162, Lys-138, or Lys-309. In contrast, in
the mutant complemented with K183A, RrgB was detectable
only as a monomer (Fig. 7), clearly indicating that Lys-183
is the residue implicated in intermolecular isopeptide bond
formation.
Moreover, in the presence of the RrgB K183A substitution
only hetero-oligomers composed of RrgA-RrgC (about 160
kDa) or RrgB-RrgC (about 110 kDa) could be detected by WB
analysis (see arrows in Fig. 7, A and C). The absence of RrgA-
RrgB heterodimers suggests that RrgA and RrgB are linked
exclusively through intermolecular isopeptide bonds involving
the D1 residue Lys-183 of RrgB.
DISCUSSION
Ever since their initial discovery, pili of Gram-positive bacte-
ria have received considerable attention because they are asso-
ciatedwith a number of different virulencemechanisms (15, 16,
33) and elicit protection in animal models (32, 49–52). In par-
ticular, the S. pneumoniae pilus was found to be implicated in
the initial attachment to epithelial cells (15, 16, 33), and the
pilus components, being protective in mouse models of infec-
tion, are regarded as potential vaccine candidates (32, 33). The
major pilin RrgB is organized into four Ig-like domains (D1–
D4), as shown by combined structural approaches (Ref. 24 and
this work). We have tested the four RrgB domains in animal
model experiments and have shown that the protective efficacy
exerted by the combination of the four RrgB domains
D1D2D3D4 is comparable with that afforded by the FL
FIGURE 6. Analysis of RrgB linker flexibility through superimposition and
modeling. A, superimposition of the D1 domain (blue) and the C. diphtheriae
SpaA N-terminal domain (red). The position of Lys-190 residue, forming the
intermolecular isopeptide bond between two neighboring SpaA molecules,
is shown along with residue Lys-183 of RrgB, which occupies a similar posi-
tion, and is indicated in a black circle. The missing loop in the SpaA crystal
structure is indicated as a gray dotted line. B, modeled conformation of the
full-length RrgB molecule obtained by combining the D1 NMR coordinates
with the RrgB D2-D4 x-ray coordinates. D1-1 and D4-1 epitopes (residues
40 –59 and 494 –508 respectively) are rendered as yellow spheres.
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RrgB.Among the single domains,D1 is themost protective, and
D4 retained an important part of the protective efficacy of the
FL protein. The lower protection achieved by D2 and D3 com-
pared with the FL protein, as well as with the D1 and D4, is
probably because the antibodies elicited by the former two
domains recognize the FL protein less efficiently, in both its
native and recombinant forms.
This may be the result of smaller exposed surface areas expe-
rienced byD2 andD3 in the FLRrgB comparedwith theD2 and
D3 isolated domains and with D1 and D4. It is possible, in fact,
that the antibodies generated against the isolated domains are
recognizing areas of D2 and D3 that are buried in the FL pro-
tein. Alternatively, D2 and D3 could assume a slightly different
conformation when expressed as single domains, thus generat-
ing nonfunctional antibodies. On the other hand, the two linear
epitopes (Fig. 6B) identified withinD1 andD4 by PepScan anal-
ysis performed with protective polyclonal antibodies raised
against the two domains (conformational epitopes are not
detectable with this method) are well exposed on the surface of
the RrgBmolecule and could contribute to the protective activ-
ity exerted by D1 and D4. Further experiments are needed to
understand to what extent these linear epitopes contribute to
the protective activity exerted by the two domains. Taken
together, these results suggest that RrgB contains multiple pro-
tective epitopes, thus confirming the potential of this vaccine
candidate. Furthermore, although the existence of possible
conformational epitopes involving residues from different
domains cannot be excluded, their contribution to the overall
protective efficacy might not be essential.
To obtain more information about the structural role of D1
and to try to correlate it with the protection data discussed
above, we solved the solution structure of this domain by using
NMR spectroscopy. D1 shows an Ig-like fold, does not contain
any intramolecular isopeptide bond, and has many flexible
regions. The observed D1 flexibility, indeed, could play a fun-
damental role in the specific antigen-antibody recognition
process (53), thus accounting forD1 enhanced protection capa-
bility with respect to the more rigid D2–D4 domains, each one
containing an intramolecular isopeptide bond. In fact, the pro-
tein structural plasticity could be related to the ability of D1 to
undergo local conformational changes and to adapt its struc-
ture to optimize the interactions with the antibodies and
increase the affinity and the specificity of the antigen-antibody
recognition process. The dynamics of D1 could therefore
strongly contribute to the interface adaptation for molecular
recognition such that the antibody can select an optimal con-
former from a wide distribution of possible D1 conformations.
The rigid structure of theD2–D4 region prevents such an effec-
tive conformational selection for these domains. The above
described phenomenon has been observed for other protein-
protein or protein-DNA interaction processes (53, 54).
To shed light on the molecular mechanism driving pilus
polymerization in S. pneumoniae, we investigated which of the
lysine residues of D1was engaged in the intermolecular isopep-
tide bond formation. Site-directed mutagenesis followed by
complementation identified Lys-183 as crucial for the pilus
assembly. This result is consistent with the observation that the
spatial position of RrgB Lys-183 can be superimposed onto Lys-
190 of the C. diphtheriae pilus backbone subunit SpaA, known
to be involved in the intermolecular isopeptide linkage (30).
Interestingly, as shown in Fig. 6A, both lysines are not fully
available to form an external bond. In particular, the average
relative solvent accessibility of the Lys-183 over theD1 family of
conformers is 27.2%  4.8, as the Lys side chain projects into a
cleft between the main body of the protein and the segment
40–78 containing the mobile loop 56–69 (27). This suggests
that pilus backbone proteins, to be polymerized,might undergo
conformational changes, probably involving not only the Lys
residue (Lys-183) but also the flexible regions spatially close to
it (49–69, 152–167, and 183–193), to allow the formation of
the covalent intermolecular isopeptide bond. NMR mobility
data indicate that the C terminus of the D1, where Lys-183 is
located, and other loops are highly mobile and that such
dynamics could be relevant for the intermolecular isopeptide
bond formation (supplemental Fig. S2). Consistently, the
absence of stabilizing intramolecular isopeptide bonds renders
D1, unlike the other domains, less rigid and prone to conforma-
tional rearrangements. Furthermore, the occurrence of a struc-
FIGURE 7. Lys-183 of RrgB is implicated in intermolecular isopeptide bond formation. WB analysis was performed using polyclonal rabbit antisera against
RrgA (A), RrgB (B), and RrgC (C). In all panels lanes are loaded as follows: 1, T4 WT; 2, T4RrgB; 3, T4RrgBRrgBWT; 4, T4RrgBRrgB(K138A); 5,
T4RrgBRrgB(K162A); 6, T4RrgBRrgB(K183A); 7, T4RrgBRrgB(K309A); 8, T4RrgBpMU1328; 9, molecular mass marker. *, RrgA monomer (estimated
molecular mass of native monomeric RrgA is 92 kDa). **, RrgB monomer (estimated molecular mass of native monomeric RrgB is 65 kDa). Arrows, the band
migrating at an apparent molecular mass of 160 kDa indicated by an arrow in lane 2 and 6 of A, and C is compatible with an RrgARrgC complex; the band at
110 kDa present in lane 6 of B and C could correspond to an RrgCRrgB complex.
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tural rearrangement of D1 within the native pilus structure is
also in line with the partial fitting of its NMR structure onto the
molecular shape of the native pilus determined by cryo-EM.
Mutagenesis and complementation data were used to ana-
lyze the covalent links established among the three pilus pro-
teins either in the absence of RrgBor in the presence of theRrgB
K183A mutant, in an attempt to provide further insights into
the possible organization of the native pilus. In the presence of
the nonpolymerizing RrgB K183A mutant, the lack of RrgA-
RrgB heterodimers provides evidence that RrgA and RrgB are
unidirectionally linked only through the Lys-183 of RrgB and
the C-terminal Thr of RrgA. This arrangement is in accordance
with the model proposed by Hilleringmann et al., positioning
RrgA at the pilus terminus, thus ruling out the alternative pos-
sibility of RrgA being incorporated along the pilus shaft (22).
Conversely, an RrgA-RrgC multimer is detectable either when
RrgB is not expressed, as already reported by Falker et al. (20)
and LeMieux et al. (55), or in the presence of nonpolymerizing
RrgB K183A. In this case, the mutated RrgB is competing with
RrgA for the linkage to RrgC, as demonstrated by the presence
of RrgB-RrgC hetero-oligomers (Fig. 7, B and C). Concomitant
detection of RrgA-RrgC hetero-oligomers even under these
conditions further strengthens the idea that in wild-type bacte-
ria, although not detectable by electron microscopy analysis of
purified pili, a fraction of RrgA and RrgC might be directly
linked to each other.
In conclusion, this study provides additional information
elucidating pilus proteins features and also paves the way to the
rational design of new RrgB-based molecules to implement a
protein-based vaccine against pneumococcal disease. More-
over, the newly acquired structural and dynamic information
on the RrgB molecule provided by this study suggests that the
conformational flexibility of D1 is pivotal for the protein-anti-
body recognition process. These findings togetherwith the new
functional information could be used to better understand pilus
functions and its role in pathogenesis.
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